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The President of the Irish 
Pharmacy Union, Mr Darragh 
O’loughlin has said that the 
union is hoping to meet with 
the newly appointed Minister 
for Health, Dr James O’Reilly 
“shortly” to begin discussions 
about a new contract for 
pharmacists. 
The union chief said that he 
understands that Dr O’ Reilly 
had indicated that he intends 
to look at a new contract for 
pharmacists and confirmed 
that the IPU has formally 
requested a meeting with the 
Health Minister to begin talks 
on this issue. 
“I understand that Dr O’ 
Reilly intends to look at a new 
contract for pharmacists and 
we are hoping to sit down 
with him shortly to discuss 
this. A number of issues will 
need to be addressed in any 
new contract. For a start, in 
creating a new contract, we 
would like to sit down with 
the Minister to discuss the 
kind of additional services 
which we believe we will 
be able to provide and how 
this can fit into the Minister’s 
agenda regarding improving 
care with the delivery of 
community care centres. For 
example, we are in a position 
to take some capacity from 
GPs in terms of delivering 
vaccines as well as other 
areas,” explained Mr O’ 
loughlin. 
Pay, according to the 
pharmacist and IPU head, 
would also definitely be an 
issue, which needs to be 
discussed very seriously. “Pay 
is always an issue and this is 
something which we will also 
be discussing. What we have 
already made very clear at this 
stage is that there is simply, 
absolutely no room for adhoc 
unilateral cuts to pharmacists 
contracts,” he said. 
A spokesperson for the 
Department of Health said 
that they were not aware of 
any official statement made 
by the Minister for Health, 
Dr James O’Reilly about any 
plans to look at the current 
contracts for pharmacists. 
However, since taking office 
earlier this year, the Minister 
for Health, Dr O’Reilly has 
already indicated that he is 
very supportive of expanding 
the role of pharmacists. 
Even in his first television 
interview as Health Minister 
on RTE news (16 March 2011), 
Dr O’Reilly said he believed, 
“pharmacists could be very 
much involved in vaccinations 
and other areas of chronic 
illness care “ going forward. 
union eager to 
discuss new contracts 
dr James o’reilly, td
darragh o’loughlin
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In BRIEF
More than 200 delegates from 
across the country are set to 
descend on Kilkenny this May 
for the Irish Pharmacy Union’s 
(IPU) inaugural pharmacy 
conference.
This major, new, pharmacy 
event, which will be opened by 
the Minister for Environment, 
Community and local 
Government, Phil Hogan TD, is 
set to address and examine all 
the major issues affecting Irish 
pharmacists today.
Amongst the key events set 
to take place over the course 
of the two-day conference are 
new business and continued 
education sessions, which aim 
to advise pharmacists on the 
latest news and advice with 
regard to running a successful 
business and keeping up 
with continued professional 
development. 
A major panel discussion, 
which aims to address and 
discuss all the burning issues 
affecting pharmacists at 
present, will also take place 
on the second day of the 
conference. A number of high 
profile names have already 
been added to the panel for 
this event including Paddy 
Burke, Assistant national 
Director Finance, PCRS, IPU 
President Darragh O’loughlin, 
Gavin Duffy of Dragon’s Den 
fame and noeleen Harvey, 
President of the PSI as well as 
Ivan yates who will chair the 
discussion. 
Speaking ahead of the 
conference, Kathy Maher, 
Chairperson of the conference’s 
organising committee said 
that the promotion for the 
inaugural conference has 
already been very well received 
by pharmacists and those 
involved behind the scenes 
believe that the new style of 
conference is set to prove very 
popular. 
“In the past the focus of 
our conference has normally 
been the AGM, but this year, 
we have introduced a number 
of completely new aspects 
including talks on continued 
education, business and 
training. We’ve also introduced 
a significant social function 
to the conference as we feel 
that it provides an important 
opportunity for pharmacists, 
many of whom often work 
in isolation, to meet with 
peers and discuss the issues 
impacting on them. 
“We’ve already received 
a fantastic response to the 
conference agenda and people 
have been very welcoming 
of the style of the conference 
which is so new. I think part 
of this is because pharmacists 
are working in a very different 
climate now and are interested 
in looking at new ways to 
improve their business,” she 
said. 
Asked what the key 
discussions would likely be at 
this year’s panel discussion, 
Ms Maher said that while at 
this stage it is still difficult to 
grasp the big issues which 
will be brought up, that it was 
likely that this would include 
issues surrounding payment 
and the future of the sector. 
“Pharmacists are working in a 
very challenging environment 
and because it is still a few 
weeks away to the conference 
it is difficult to pinpoint exactly 
what the discussion will 
surround, but it is likely that 
amongst the issues which will 
top the agenda are payment 
to pharmacists, the stability 
of the sector, the future of 
pharmacy practice in Ireland 
and how pharmacists are 
going to adopt a more patient 
centered approach as well as 
how to provide new access to 
medicines,” she said. 
The IPU Pharmacy 
Conference takes place on May 
7 and 8 at the lyrath Estate 
Hotel in Kilkenny. For further 
information log on to www.
pharmacyconference.ie
Ipu to host first major 
national conference
pictured at the Introduction course for pharmacy liaisons in the Clinical Care 
programmes, hosted by the royal College of physicians of Ireland in Association with the 
health Service Executive and the pharmaceutical Society of Ireland was dr. Barry White, 
National director of Clinical Strategy and programs, hSE.
Pic. Maxwells Dublin
pharmacy liasons
only one third of patients 
returning unwanted meds
A new study has found that 
only a third of patients are 
returning unwanted medicines 
to their pharmacists. 
The new research, which 
was conducted by second 
year medical students at nUI 
Galway, Sarah Cormican and 
Michelle Furey, showed that 
while a significant proportion of 
people have leftover medicines 
in their home, over half of these 
respondents reported disposing 
of unwanted medicines along 
with general household waste, 
by flushing down toilets and 
sinks, or by burning.
The study was undertaken 
in the context of international 
reports which show that many 
people do not know that un-
wanted medicines should not be 
by thrown into household waste 
or flushed down toilets or sinks 
because of the biological risks 
this poses to the environment. 
New measures recommended 
for pandemrix
The European Medicine Agency 
has recommended that the 
product information for Pan-
demrix should be amended to 
advise prescribers to take into 
account preliminary results from 
new studies on Pandemrix and 
narcolepsy, and to perform an 
individual benefit-risk assess-
ment when considering the use 
of Pandemrix in children and 
adolescents.
The move is an interim 
measure pending the outcome 
of the European review, which is 
expected to conclude in July 2011.
New medicinal garden 
opens at tCd 
Dr Henry Oakeley, Garden Fellow, 
Royal College of Physicians of 
london visited Trinity College 
Dublin in April to open the uni-
versity’s new medicinal garden. 
The new garden displays 
60 plants of medicinal interest 
including Humulus lupulus, Hy-
pericum perforatum and Salvia 
officinalis. 
Dr Oakeley has worked with 
plants for nearly 60 years and 
is responsible for looking after 
the garden at the Royal College 
of Physicians of london which 
has a thousand plants used as 
medicines at some time in the 
past millennia.
Following the opening, Dr 
Oakeley gave a special, public 
lecture at the university entitled, 
‘Why Plants Have Been Used as 
Medicines for the Past 3,000 Years?’
positive 
opinion 
for weekly 
diabetes 
treatment 
The European Medicine’s 
Agency has announced that 
it’s Committee for Medicinal 
Products for Human Use (CHMP) 
has adopted a positive opinion 
for the marketing of a new once-
weekly diabetes treatment. 
The move follows on from an 
application by Eli lilly and Com-
pany, together with Amylin Phar-
maceuticals and Alkermes for 
marketing authorisation for the 
medicine, Exenatide. If approved, 
exenatide for prolonged release 
would be the first once-weekly 
type 2 diabetes treatment. 
The CHMP’s positive opinion 
is now referred for final action 
by the European Commis-
sion, which has the authority 
to approve medicines for the 
European Union. If approved, 
the treatment is planned to be 
marketed in the European Union 
under the proposed brand name 
Bydureon. 
For Actavis, each of its markets is special and unique. That’s why 
we have a sales and marketing presence in more than 40 countries 
around the world, working face-to-face with our customers and 
With our global strength anchored in these well established local 
roots, Actavis continues to achieve healthy growth and set the pace 
for development in the generic pharmaceutical industry.
Actavis Ireland Ltd.
Euro House
Euro Business Park
Little Island
Cork
T 1890 33 32 31     
F 021 4619049
@ contact@actavis.ie
A
D
 T
RE
E0
02
.1
0.
09
issue 5 volume 13 • mAY 2011
6
newsne s
More than 160 delegates from 
across the country descended 
on Dublin in April for the 
annual Hospital Pharmacists 
Association of Ireland (HPAI) 
conference and AGM. 
This year’s conference 
featured a number of intense 
educational workshops, plenary 
sessions and presentations as 
well as a very well subscribed 
poster competition. 
On the first day of the 
conference, delegates 
undertook a series of 
workshops on topics, which 
included compounding, 
microbiology and 
thromboprophylaxis. 
That evening, delegates 
enjoyed a gala dinner at the 
Crowne Plaza Hotel in Santry 
where the newly appointed 
Minister for Health, Dr James 
Reilly, TD was the guest of 
honour. 
On the second day of 
the conference, delegates 
attended a number of 
presentations including 
a session on continuing 
professional development 
for pharmacists which 
was presented by lorraine 
Horgan, Head of Professional 
Development & learning, 
Pharmaceutical Society of 
Ireland. This was followed by 
the highly regarded Servier 
Pharmaceutical Care Award 
2010 presentation which, 
this year, was presented on 
the application of electronic 
guidelines in Antimicrobial 
Stewardship.
That afternoon, the 
winners of this year’s HPAI 
poster competition were also 
announced. This year, a total of 
62 posters were entered into 
the competition, with some 
authors submitting as many as 
three entries. 
Helen Danaher, Mater 
Misericordiae University 
Hospital, Dublin scooped 
the top prize in the 
research category of the 
competition (sponsored 
by GlaxoSmithKline) for 
her poster entitled Statin 
optimisation in Type 2 Diabetes 
Mellitus Outpatients. Jennifer 
Brown, also of the Mater 
Misericordiae took the first 
place accolade in the audit 
category (sponsored by B 
Braun) for her poster, A review 
of pharmacist cancelling 
dangerous prescriptions 
process at the MMUH and the 
first place in the Innovation 
in practice / professional 
Development category for 
her poster, Development and 
implementation of a nutritional 
chart in the Mater Misericordiae 
University Hospital. The top 
award in the Intern Pharmacist 
Project 2009-2010: Mary Harte 
Award was bestowed on Breda 
Bourke, AMnCH, Tallaght for 
her poster, A baseline audit 
of vancomycin dosing and 
therapeutic drug monitoring at 
AMNCH whilst the top award in 
the Pharmaceutical Technician 
competition (sponsored 
by Baxter Healthcare) was 
awarded to Martina McCabe, 
pharmaceutical technician, 
also of AMnCH, for her poster, 
A re-audit of the turnaround 
time for urgent medication 
orders brought to the pharmacy 
reception.
Speaking after the 
conference, HPAI 
spokesperson, Eileen Butler 
said that this year’s conference 
had proved a great success. 
“Our remit is to further the 
development of hospital 
pharmacy and pharmacists 
and I think that our conference 
did just that. This year’s event 
included a wide spectrum 
of events and educational 
components which were very 
well attended and received.”
Education dominates agenda at hpAI conference 
In BRIEF
new Irish research has found 
that 70 per cent of older 
people in nursing homes in 
Ireland are taking at least one 
inappropriately prescribed 
medicine. 
According to the study, 
which was funded by the 
Centre for Ageing Research 
and Development in Ireland 
(CARDI), 73 per cent of 
residents in nursing homes 
in the Republic of Ireland 
were receiving at least one 
potentially inappropriate 
medicine. In northern Ireland, 
67 per cent of those in the 
sample were receiving a 
potentially inappropriate 
medicine.
Overall, nearly one fifth 
(19 per cent) of the sample 
were receiving three or more 
potentially inappropriate 
medicines.
The study, which was led by 
by Dr Stephen Byrne, Senior 
lecturer in Clinical Pharmacy 
at University College Cork, also 
found that some 630 older 
people in long-term care in 
northern Ireland and the Cork 
area were receiving an average 
of 11 medicines each. Half of 
these people were prescribed 
8-14 daily medicines each.
Commenting on the new 
research, Dr Stephen Byrne 
said that the global problem 
of inappropriate prescribing 
can put older people in 
serious danger and that a 
multi-disciplinary approach by 
pharmacists, doctors, nurses 
and healthcare professionals 
was vital in addressing this 
ongoing problem. “Potentially 
inappropriate prescribing 
can lead to both minor and 
serious adverse drug events for 
older people. One of the most 
common instances is the risk 
of falls and fractures, leading 
to extended hospitalisation,” 
he said. 
Responding to the study, Irish 
Pharmacy Union President, Mr 
Darragh O’ loughlin described 
the findings as ‘concerning’.
“If patients are taking 
inappropriate medication 
their health may be at risk. 
The Irish Pharmacy Union 
calls on the Minister for Health 
to implement proposals to 
introduce pharmacist led 
Medicine Use Reviews for 
patients who are using multiple 
medications. The introduction 
of this initiative which has been 
advocated by the IPU in recent 
years will highlight problems in 
a patient’s medication regime 
and, lead to safer and more 
cost effective medicine use, 
better outcomes for patients 
and fewer hospital admissions,” 
he said. 
The cost of the inappropriate 
medicines has been determined 
as €170 per older person in the 
northern Ireland sample and 
€356 in the Republic of Ireland 
sample. 
>> See page 20 and 21 for an 
extended feature looking at the 
future of pharmacist led MURs.
70 per cent of older people 
taking ‘inappropriate’ meds
Novartis withdraws 
marketing application for 
Joicela
novartis has withdrawn its 
marketing authorisation 
application to the European 
Medicine’s Agency for the 
medicine Joicela (lumiracoxib). 
Joicela was intended to be 
used for symptomatic relief in 
the treatment of osteoarthritis 
of the knee and hip in patients 
who are non-carriers of the 
DQA1*0102 allele.
The application for the 
marketing authorisation for 
Joicela was submitted to the 
Agency on 3 December 2009. 
At the time of the withdrawal 
it was under review by the 
Agency’s Committee for 
Medicinal Products for Human 
Use (CHMP).
In its official letter to the 
EMA, novartis said its decision 
to withdraw the application 
was based on its inability to 
address the CHMP’s request to 
provide additional data within 
the timeframe allowed in the 
centralised procedure.
Major funding boost for 
helix health 
Healthcare software solutions 
company, Helix Health,  has 
announced it has raised €5 
million of equity funding 
from The Ulster Bank Diageo 
Venture Fund, managed by 
nCB Ventures. 
The funding will be used to 
strengthen Helix Health’s 
investment in driving export 
sales and to facilitate further 
investment in R&D projects.  
Commenting on the 
announcement Howard Beggs, 
CEO, Helix Health said,  “This 
investment by The Ulster Bank 
Diageo Venture Fund is a very 
significant step in the growth 
story of Helix Health. It will 
facilitate further investment in 
our products to support local 
and international expansion.”
Helix Health products are 
currently used by over 10,000 
healthcare professionals 
and their systems are used 
in 70 per cent of pharmacies 
across Ireland and the United 
Kingdom.
Helix Health was established 
in 2007 as a result of the 
merger between Systems 
Solutions and Medicom, 
becoming Ireland’s largest 
healthcare IT provider 
and an emerging player in 
international markets. 
Elaine Conyard, president of the hpAI speaking at the 
hpAI conference 2011 at the Crowne plaza, Santry, dublin 
this April.
Scientifically 
re-formulated to 
more closely reflect 
the composition of 
breast milk.
I N T R O D U C I N G 
New Formula SMA First Infant Milk from
MADE IN 
IRELAND
1
2
3
IMPORTANT NOTICE: Breastfeeding is best for babies. Good maternal nutrition is important for the preparation and maintenance of breastfeeding. 
Introducing partial bottle-feeding may have a negative effect on breastfeeding and reversing a decision not to breastfeed is difficult. You should always 
seek the advice of a doctor, midwife, health visitor, public health nurse, dietitian or pharmacist on the need for and proper method of use of infant milks 
and on all matters of infant feeding. Social and financial implications should be considered when selecting a method of infant feeding. Infant milk should 
always be prepared and used as directed. Inappropriate foods or feeding methods, or improper use of infant formula, may present a health hazard.
† Alpha-lactalbumin
References: 
1. Yao M, R Capeding, M Fitzgerald, 
K Ramanujam, S Yachetti, P DeRusso. 
2010. High 2-palmitate and oligofructose 
in lower protein alpha-lactalbumin-enriched term 
infant formula: effects on stool characteristics and stool 
composition. J Pediatr Gasterenterol Nutr 50(Suppl 2):E207-208.
2. Trabulsi J et al. Effect of an alpha-lactalbumin-enriched infant formula 
with lower protein on growth. Eur J Clin Nutr 2011; 65: 167-74.
3. Kullen M et al. Characterization of peptides derived from alpha-lactalbumin 
digestion and demonstration of their prebiotic effect through stimulation of 
bifidobacteria in a model of the gastrointestinal tract. J Pediatr Gastroenterol  
Nutr 2009; 48(suppl 3): E88, 0P3-06.
4. Bettler J, Kullen MJ. Infant formula enriched with alpha-lactalbumin has a prebiotic  
effect in healthy term infants. J Pediatr Gastroenterol Nutr 2007; 44(Suppl.1): e197. PN1-11.
PFN0082/04/11
New Fat blend  
That leads to a softer stool consistency, closer to that of a breastfed baby.1
Whey protein profile closer to human milk  
Delivering a slower early weight gain velocity, closer to that of breastfed 
infants, than infants fed standard whey-dominant formula.2
Prebiotic effect 
Enriched with alpha-protein†, which is thought to  
stimulate the growth of bifidobacteria during digestion.3   
Over 8 weeks, new SMA First Infant Milk was shown  
to have a prebiotic effect, similar to that  
seen in breastfed infants.4
Simply  
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In the best of health
Well known celebrity, Calum 
Best visited McCabe’s 
Pharmacy in Dundrum Town 
Centre this month to help 
launch the pharmacy’s new 
health screening services 
which include a food 
intolerance test, a thyroid 
health test and a prostate 
health test.
The new prostate screening 
service is Ireland’s first 
pharmacy-based PSA test. The 
test monitors the PSA levels in 
the blood and provides results 
in ten minutes. 
The thyroid health test 
measures TSH levels and 
results are available in five 
minutes.
The food Intolerance test 
features screening for up to 
93 food groups and is one of 
the most comprehensive food 
intolerance tests available.
Pictured here launching the 
new health check services are 
Calum Best and Olga Bennett, 
McCabe’s Pharmacy Dundrum.
Further information available on request.  
Chefaro Ireland Limited, Farnham Drive, Finglas, Dublin 11.
Tel: 01 879 0647 Fax: 01 836 2310 Email: info@omega-pharma.ie
Visit our website: www.wartner.ie
*   Source: IMS MAT 12/10 
** In Vivo Clinical Study Omega Pharma NV 2010
n  New innovative TCA  
(Trichloroacetic Acid) Gel Treatment
n  Effective from the first week
n  Suitable for children from  
4 years of age
n  94% of patients tested were  
very satisfied with the efficacy  
of the Wartner Verruca and  
Wart Pen**
Wartner Verruca & 
Wart Removal Pen 
n  Easy to use 4 step application
n  Only 1 drop of gel required per  
application
n  Effective from the first week
n  85% of patients tested in 
the first week experienced a 
complete removal of corns 
and persistent calluses**
Wartner  
Corn Removal Pen 
Campaign
HeavyweigHt
Wartner IP Trade Advert.indd   1 22/03/2011   15:34:58
For more information contact:
Jennifer Hughes at T: +353-1-4633000   F: +353-1-4633011   E: jennifer.hughes@helixhealth.com   
W: www.helixhealth.com  Helix Health Limited  52 Broomhill Road, Tallaght, Dublin 24, Ireland. 
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Pictured at the nAHPT 
conference are Jennifer 
O'Meara, Pharmacy Technician, 
AMnCH, Rebekah Corrigan, 
Pharmacy Technician,Connolly 
Hospital, Eglina Corrigan, 
Pharmacy Technician, Galway 
University Hospital, Marie 
Mclaughlin, Pharmacy 
Technician, Galway University 
Hospital; Front: yvonne 
Sheehan, Pharmacy Technician, 
AMnCH, Fran Glynn, President 
nAHPT, laura lyons, Pharmacy 
Technician, Mater Public
By Brid Ni Luasaigh
In BRIEF
The future of continued profes-
sional development for hospital 
pharmacy technicians was 
amongst one of the key topics 
discussed by technicians at the 
recent national Association of 
Hospital Pharmacy Technicians 
annual conference. 
Over the course of the one-
day event, pharmacy technicians 
reflected on how continued 
professional development is 
changing and developing within 
their own sector and looked at 
the part they would need to play 
to ensure that they can continue 
to ‘step up’ and meet the grow-
ing educational demands on 
them. 
This reflection and discussion 
was supported with a key pres-
entation by Caitriona Gowing, 
Senior Clinical Pharmacist from 
AMnCH in Tallaght who dis-
cussed the topic, CPD and you. 
At the meeting Julie Jordan, 
co-ordinator for pharmacy 
technician education and train-
ing, nI Pharmacy Training and 
Development Centre (nICPD) 
also presented a talk about 
CPD opportunities available 
to pharmacy technicians in 
northern Ireland including the 
course for ‘Accredited Checking 
Technicians’, which she offered 
to deliver to pharmacists in the 
south. Talks between the nICPD 
and the nAHPT are ongoing in 
relation to this.
Another highlight of this year’s 
event was the annual nAHPT 
poster competition awards, 
which, was sponsored by Actavis. 
Commenting on the success 
of this year’s competition, Fran 
Glynn, President of the nAHPT 
said, “This was the first year we 
opened our poster competition 
to student pharmacy techni-
cians. We had five poster entries 
and I am sure that will grow. 
We had a great response from 
hospital pharmacy technicians 
and there were ten poster entries 
all to a very high standard from 
these. This was our first year for 
our poster competition to be 
sponsored by a pharmaceuti-
cal company. It was sponsored 
by Actavis with a brilliant prize 
of €500 which was won by 
Blathnaid McIntyre from AMnCH 
Tallaght.”
Amongst the other key 
issues discussed at this year’s 
conference were medicine 
management, Clozapine and the 
pharmacy technicians’ role and 
finally, career motivation. 
FIp Congress 2011
Details of this year’s 
annual FIP World 
Congress of Pharmacy and 
Pharmaceutical Sciences have 
just been announced. 
The theme of this year’s 
congress is Compromising 
safety and quality: a risky 
path.
Amongst the issues which 
will be discussed over the six 
day event are communicating 
basic medicines information 
to patients, innovations in 
teaching and learning and 
paying pharmacists for 
patient outcomes. 
This year’s event, the 71st 
International Congress, will 
take place at Hyderabad, 
India from September 3 to 8. 
For further details log on to 
www.fip.org/hyderabad2011/
Support urged for new pain 
campaign 
People across Ireland are 
being urged to lend their 
support to a major new 
Europe-wide campaign, 
which aims to raise awareness 
of the burden of chronic pain. 
Supported by Chronic Pain 
Ireland and Pfizer Healthcare 
Ireland, the Can You Feel My 
Pain? campaign aims to give 
a voice to 13 per cent of the 
Irish population (400,000) 
who are living with the 
debilitating condition. 
As part of this new 
campaign, people across 
Ireland are being encouraged 
to help raise awareness of the 
difficulty of pain and show 
their support for the initiative 
by helping to develop a new 
Bill of Rights by signing an 
online petition hosted on 
www.chronicpain.ie 
New 
antibiotics to 
tackle drug 
resistant tB
Cork td appointed as 
Minister for older people 
Cork labour TD, Deputy 
Kathleen lynch has been 
appointed as the new 
Minister for Older People. 
Minister lynch’s priority 
will be to complete and 
implement the national 
Positive Ageing Strategy as 
outlined in the Programme 
for Government. 
Her responsibilities also 
include ensuring the supply 
of more and better care 
for older people in the 
community and in residential 
settings.
The Irish Pharmacy Union (IPU) 
has strongly criticised the latest 
tranche of cuts to pharmacists’ 
payments under the Financial 
Emergency Measures in the 
Public Interest Act 2009 (FEMPI) 
saying that the cuts will “impose 
hugely disproportionate pain on 
community pharmacists.”
Under the latest measures 
announced as part of FEMPI, the 
HSE will be reducing a number 
of payments made to communi-
ty pharmacy contractors under 
the General Medical Services 
(GMS) and community drugs 
schemes including a reduction 
from 50 per cent to 20 per cent 
in the retail mark-up pay-
able under the Drugs Payment 
Scheme and the long Term 
Illness Scheme in respect of non-
drug items, controlled drugs and 
fridge items. The measures will 
also result in a 50 per cent reduc-
tion in the patient care fee under 
the high-tech medicines scheme 
for months when medicine is 
not dispensed and a reduction 
from 10 per cent to 8 per cent in 
the wholesale mark-up payable 
in respect of drugs dispensed 
under the GMS and community 
drugs schemes.
Responding to the announce-
ment, IPU president, Darragh O’ 
loughlin said that the wholesale 
margin is not being reduced as 
stated in the department’s press 
release, but that what is being 
reduced is the very price that 
the HSE pays to pharmacists for 
dispensing medicines on the 
community drugs schemes.
He added, “The IPU made a 
detailed submission in January 
to the Minister entitled ‘Time 
for a New Approach’. We clearly 
demonstrated that there is no 
scope for further unilateral and 
arbitrary cuts. Pharmacists have 
already suffered direct and 
indirect cuts of 32 per cent or 
€153m since July 2009, which 
is more than that suffered by 
any other part of the health 
sector. now we are being cut by 
another €36m. We have clearly 
said that additional efficiencies 
and savings can be achieved by 
adopting a new approach. This 
approach would involve a sub-
stantial and direct engagement 
with the IPU within a defined 
period of time to review all exist-
ing, administrative, contractual 
and payment arrangements.”
Concluding, Mr O’ loughlin 
added that he believed that in 
focusing on cuts and ignor-
ing the capacity of commu-
nity pharmacy to deliver many 
primary care treatments more 
cost effectively and conveniently 
for patients, these cuts were 
undermining the capacity of the 
most accessible part of Ireland’s 
primary care service.
“Community pharmacists 
are angry that an opportunity 
to deliver savings in ways that 
would meet patients’ needs 
more effectively has been jet-
tisoned. These cuts will entrench 
instead of challenging outdated 
patterns of primary care deliv-
ery. The capacity of a nationwide 
community pharmacy network 
to deliver primary care cost ef-
fectively has been ignored and 
undermined by these further 
ill-conceived cuts in payments 
to pharmacists. I sincerely hope 
that today’s cuts mark the end 
of an ad hoc series of cuts to 
pharmacy payments and that 
the Minister will now engage 
with the IPU on an agenda for 
change,” he said. 
Cpd comes under the spotlight 
at NAhpt conference 
Ipu say FEMpI cuts imposing 
‘disproportionate pain’
Two new, EU-funded research 
projects have found new an-
swers in the fight against drug 
resistant tuberculosis.
At a time when it is estimated 
that drug resistant infections 
cause more than 25,000 deaths 
in the European Union alone, 
the first of these projects, 
nM4TB, has identified new 
substances to tackle drug 
resistant TB.
The study, which gathers 18 
research teams from 13 coun-
tries, discovered a novel class of 
substances, called benzothiazi-
nones (BTZ), that could be used 
in the treatment of tuberculosis 
and drug resistant tuberculosis.
The second project, Actino-
GEn, involves discovering and 
developing new antibiotics. As 
part of this study, researchers 
from nine European countries 
and the Republic of Korea are 
currently exploiting the genetic 
resources of a group of bacteria 
called actinomycetes. It is be-
lieved that these new bacteria 
could play a pivotal role in the 
fight against antibiotic resistant 
bacteria. 
We
■ are a one-stop service for exempt sourced medicinal products1
■ supply manufactured specials/extemporaneous products within 24-48hrs
■ have experienced  support staff to manage the intricacies associated with handling exempt sourced
medicinal products in an ethical and professional manner from the initial request, through to the
supply of the medicine
■ source, import and supply irregular and once off products
■ no extra delivery charges using customers current delivery arrangements
■ provide a first class cold chain service
If you are a hospital or community pharmacist, doctor, dentist or a veterinarian and you have a product
enquiry or order, contact your local CMR telesales office or the Alchemy specialist team and we will then
source, price and oversee the delivery of your order making sure you get what you need quickly and
cost-effectively.  Working with Alchemy and CMR provides you with instant access to a multitude of
international possibilities to fulfil your exempt sourced medicinal products requests.
CMR & Alchemy operates in line with Irish Medicines Board (IMB) guidelines.
1 S.I. No. 538 of 2007: MEDICINAL PRODUCTS (CONTROL OF WHOLESALE DISTRIBUTION) REGULATIONS 2007, (SEC 2 (17)).
Contact/Order Details: Alchemy Direct Dial: (01) 630 5432
Telesales Number: (071) 916 1801
Order Fax Number: (071) 916 1977
E-mail Orders: alchemy@cmrg.ie
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In BRIEF
Independent, community 
pharmacists in the US have 
secured top marks in a new 
consumer survey. 
The results of the survey, which 
was undertaken by readers of 
Consumer Reports magazine, 
showed that more than 90 
per cent of those surveyed 
were highly satisfied with their 
experiences at independent 
pharmacies in areas including 
personal service, knowledge and 
speed in filling prescriptions.
The 43,739 survey 
respondents also said they found 
independent pharmacies offered 
lower prices than traditional, 
national pharmacy and that 
overall, they found independent 
pharmacists were competitive on 
pricing.
Commenting on the survey 
results, national Community 
Pharmacists Association (nCPA) 
Executive, Vice President 
and CEO Douglas Hoey said, 
“Independent community 
pharmacists are dedicated to 
providing patients with expert 
medication counseling and 
sterling customer service.
“It's encouraging and 
gratifying to see that patients 
notice and appreciate these 
efforts. We congratulate 
independent pharmacists 
throughout the country on this 
distinguished recognition from 
their patients."
The survey's findings are 
consistent with those of the 
2010 JD Power and Associates 
Pharmacy Study. In that survey, 
patients gave among the 
highest satisfaction scores to 
independently owned, locally 
operated pharmacies.
Wales has joined ranks with 
Scotland and with many parts 
of England in introducing 
free emergency hormonal 
contraception facilities. 
As part of a new policy 
measure by the Welsh govern-
ment, women over the age 
of 13 can be provided with 
emergency contraception and 
sexual health advice free of 
charge at pharmacies in Wales.
The move forms part of an 
initiative to reduce the number 
of teenage pregnancies in 
Wales, which hosts the highest 
rate of teen pregnancies in the 
United Kingdom.
The service is already 
offered free of charge in 
Scotland and in many PCTs in 
England.
Commenting on the deci-
sion, Steve Simmonds, nPA 
Representation Manager in 
Wales said, "the decision in 
Wales is a clear endorsement 
of the expertise and unique ac-
cessibility of community phar-
macy. Although this service 
is already offered in Scotland 
and in many parts of England, 
we'd like to see it everywhere 
in the UK free of charge."
prescription charge 
abolished in Scotland
New medicines quality 
database established
A new database, which shows 
the quality of medicines 
around the world, has just been 
launched. 
The facility, the Medicines 
Quality Database (MQDB), 
provides information to health 
professionals and the public 
about the quality of medicines, 
which have been collected and 
analysed at a number of global 
locations including Ghana, 
laos, Vietnam, Cambodia, the 
Philippines, Thailand, Peru, 
Guyana and Colombia. 
The launch of the database 
comes at a time that more and 
more poor quality medicines, 
both substandard and counter-
feit, are making their way into 
pharmacies and other outlets 
in developing countries. 
The database, which has 
been launched by Promot-
ing the Quality of Medicines 
(PQM), is supported by USAID 
and implemented by the US 
Pharmacopeial Convention 
(USP). It can be accessed at 
http://www.usp.org/world-
wide/medQualityDatabase/
English pharmacists want 
formal role in public health 
Marketing authorisation 
application for anaemia 
drug withdrawn
The European Medicines Agen-
cy (EMA) has announced that 
it has been formally notified by 
Reliance GeneMedix Plc. of its 
decision to withdraw its applica-
tion for a centralised marketing 
authorisation for the medicine 
Epostim (erythropoietin). 
The medicine was intended 
to be used for a number of 
indications including the treat-
ment of anaemia, to increase 
the yield of autologous blood 
from patients in a predonation 
programme and  to reduce 
exposure to allogenic blood 
transfusions in adult non-iron 
deficient patients prior to major 
elective orthopaedic surgery.
The application for the mar-
keting authorisation for Epostim 
was submitted to the Agency 
on 29 October 2010. At the time 
of the withdrawal it was under 
review by the Agency's Com-
mittee for Medicinal Products 
for Human Use (CHMP).
In its official letter, the com-
pany stated that its decision to 
withdraw the application was 
based on its inability to address 
the CHMP's request to provide 
additional data within the time-
frame allowed in the centralised 
procedure.
Prescription charges have 
been abolished in Scotland as 
part of efforts by the Scottish 
Government to improve the 
health of the nation. 
The move, which took 
effect in April 2011, follows 
a planned phasing out of 
prescription charges by the 
government, which com-
menced back in 2008. 
This latest initiative has 
seen Scotland join Wales and 
northern Ireland in providing 
free prescriptions to patients 
and means that England 
remains the only part of the 
UK, which continues to have a 
prescription charge. 
The move has been warmly 
welcomed by pharmacists in 
the UK who say that the action 
will help ensure patients in 
Scotland get the medicines, 
which they need. Pharmacists 
say however, that they are dis-
appointed that the move has 
not been followed in England. 
nanette Kerr, Director of 
Pharmacy at the national 
Pharmacy Association said, 
“We welcome the news that 
from today, people in Scotland 
will no longer have to pay for 
their prescriptions. Prescrip-
tion charges deter many peo-
ple from getting medicines, 
which their doctor prescribes. 
Patients on low fixed incomes 
who do not qualify for exemp-
tion suffer the most. 
“It is therefore disappoint-
ing that people in England 
will see prescription charges 
rise to £7.40 today. From a 
pharmacist’s point of view, 
processing prescription levies 
is part of the job that adds 
workload but no patient 
benefit. 
“Pharmacists, like other 
health care professionals, 
experience great pressures 
on their time and any release 
of time could be used to en-
hance patient care.”
The English Pharmacy Board 
has called on the Department 
of Health in the UK to ensure 
that pharmacists are given a 
formal role in public health.  
The move follows on from 
a three-month consultation 
period regarding the publica-
tion of the UK Department of 
Health’s latest policy docu-
ment Healthy Lives, Healthy 
People: a strategy for public 
health in England. 
This document, which was 
published in December, sets 
out how the department aims 
to strengthen public health 
provision into the future via 
a new national Public Health 
Service.
Responding to the docu-
ment, Chair of the English 
Pharmacy Board (EPB), lindsey 
Gilpin said that while the EPB 
supports the document, it 
believes that the department 
must ensure that this new pub-
lic health services utilises the 
network of community phar-
macies as its natural frontline. 
 “Community pharmacists 
are highly qualified health 
professionals who lead well 
trained teams already deliver-
ing public health services on a 
daily basis from very accessible 
and convenient locations.
“Informal public health 
provision has been central to 
pharmacies throughout their 
history and there is a growing 
evidence base for good out-
comes from their delivery of 
formal public health services,” 
she said. 
Continuing, the pharmacy 
body chair added, “Increasing-
ly, public health interventions 
will require the use of medi-
cation. Pharmacists are the 
experts in medicines and have 
a great deal of public health 
expertise within primary care, 
especially in service design 
and improvement, which does 
not appear to be recognised in 
this White Paper.
 “The contributions pharma-
cists in Great Britain already 
make at strategic and commis-
sioning levels in wider public 
health must be recognised 
and supported in the new nHS 
structures in England. These 
include needs assessments, 
public health policy and 
planning, quality frameworks, 
evidence-based delivery and 
medicines management.”
Emergency 
pill now free 
in Wales 
top marks for independent pharmacists 
Cialis offers your patients
Proven efficacy from 30 minutes up to 36 hours with sexual stimulation1
Greater sexual self-confidence and spontaneity than sildenafil2
CIALIS* (TADALAFIL) REPUBLIC OF IRELAND ABBREVIATED PRESCRIBING INFORMATION
Presentation Tablets 2.5mg, 5mg, 10mg, or 20mg of tadalafil.  Also contains lactose. Uses Treatment of erectile dysfunction in 
adult males. Dosage and Administration Adult men: The recommended dose is 10mg orally, taken at least 30 minutes prior to 
sexual activity.  In those patients in whom tadalafil 10mg does not produce an adequate effect, 20mg might be tried. Maximum 
dosing frequency, once per day. 10mg or 20mg tadalafil is not recommended for continuous daily use. In patients who anticipate 
a frequent use of Cialis (ie, at least twice weekly), a once daily regimen with the lowest doses of Cialis might be considered. The 
recommended dose is 5mg taken once a day at approximately the same time of day. The dose may be decreased to 2.5mg once 
a day based on individual tolerability. The appropriateness of continued use of the daily regimen should be reassessed periodically. 
Elderly: Dosage adjustment not required. Impaired renal or hepatic function: In patients with severe renal impairment the maximum 
recommended dose is 10mg.  Once a day dosing of Cialis is not recommended in patients with severe renal impairment.  In men 
with hepatic impairment the recommended dose is 10mg.  There are no available data about the administration of doses higher 
than 10mg of tadalafil to patients with hepatic impairment.  There is limited clinical data on the safety of Cialis in patients with 
severe hepatic impairment; if prescribed, a careful individual benefit/risk evaluation should be undertaken by the prescribing 
physician.  Once a day dosing has not been evaluated in patients with hepatic impairment; therefore, if prescribed, a careful 
individual benefit/risk evaluation should be undertaken by the prescribing physician. Diabetes: Dosage adjustment not required. 
Use in children and adolescents: Cialis should not be used in individuals below 18 years of age. Not indicated for use by women. 
In clinical trials, Cialis demonstrated improvement in patients’ erectile function and the ability to have successful sexual intercourse 
up to 36 hours following dosing. Contra-indications Known hypersensitivity to any ingredient. Patients using any form of organic 
nitrates. In men with cardiac disease for whom sexual activity is inadvisable.  Physicians should consider the potential cardiac risk 
of sexual activity in patients with pre-existing cardiovascular disease. Patients with myocardial infarction within the last 90 days, 
patients with unstable angina or angina occurring during sexual intercourse, patients with New York Heart Association class 2 or 
greater heart failure in the last 6 months, patients with uncontrolled arrhythmias, hypotension (<90/50mmHg), or uncontrolled 
hypertension, patients with a stroke within the last 6 months. Cialis is contra-indicated in patients who have loss of vision in one 
eye because of non-arteritic anterior ischaemic optic neuropathy (NAION), regardless of whether this episode was in connection or 
not with previous PDE5 inhibitor exposure. Warnings and Special Precautions Prior to any treatment for erectile dysfunction, 
physicians should consider the cardiovascular status of their patients, since there is a degree of cardiac risk associated with sexual 
activity. Tadalafil has vasodilator properties, resulting in mild and transient decreases in blood pressure.  It augments the 
hypotensive effect of nitrates. Tadalafil (2.5mg and 5mg): In patients receiving concomitant antihypertensive medicines, tadalafil 
may induce a blood pressure decrease.  When initiating daily treatment with tadalafil, appropriate clinical considerations should be 
given to a possible dose adjustment of the antihypertensive therapy. Serious cardiovascular events were reported either post-
marketing and/or in clinical trials. Although most of the patients in whom these events have been observed had pre-existing 
cardiovascular risk factors, it is not possible to determine whether these events are related directly to these risk factors, to Cialis, 
to sexual activity, or to a combination of these or other factors. Visual defects and cases of NAION have been reported in 
connection with the intake of Cialis and other PDE5 inhibitors.  In case of sudden visual defect, patients should be advised to stop 
taking Cialis and consult a physician immediately. Due to increased tadalafil exposure (AUC), limited clinical experience, and the 
lack of ability to influence clearance by dialysis, once a day dosing of Cialis is not recommended in patients with severe renal 
impairment. There is limited clinical data on the safety of single-dose administration of tadalafil in patients with severe hepatic 
insufficiency (Child-Pugh class C); if prescribed, a careful individual benefit/risk evaluation should be undertaken by the prescribing 
physician. Use with caution in patients who have conditions that might predispose them to priapism, or in patients with anatomical 
deformation of the penis. Patients who experience erections lasting 4 hours or more should be instructed to seek medical 
assistance. If priapism is not treated immediately, penile tissue damage and permanent loss of potency may result. It is not known 
if Cialis is effective in patients who have undergone pelvic surgery or radical non-nerve-sparing prostatectomy. Cialis should not be 
administered to patients with hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose 
malabsorption. In patients who are taking alpha1-blockers, concomitant administration of Cialis may lead to symptomatic 
hypotension in some patients.  The combination of tadalafil and doxazosin is not recommended. Caution should be exercised when 
prescribing Cialis to patients using potent CYP3A4 inhibitors (ritonavir, saquinavir, ketoconazole, itraconazole, and erythromycin) 
as increased tadalafil exposure (AUC) has been observed if the drugs are combined. The safety and efficacy of combinations of 
tadalafil and other PDE5 inhibitors or other treatments for erectile dysfunction have not been studied.  Patients should be informed 
not to take Cialis with such combinations. Pregnancy and Lactation Not indicated for use by women. There are limited data from 
the use of tadalafil in pregnant women.  Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, 
embryonal/foetal development, parturition, or postnatal development. As a precautionary measure, it is preferable to avoid the use 
of Cialis during pregnancy. Available pharmacodynamic/toxicological data in animals have shown excretion of tadalafil in milk.  A 
risk to the suckling child cannot be excluded.  Cialis should not be used during breast-feeding. Driving, etc No studies on the effect 
on the ability to drive and use machines have been performed. Although the frequency of reports of dizziness in placebo and 
tadalafil arms in clinical trials was similar, patients should be aware of how they react to Cialis before driving or operating machinery. 
Undesirable Effects Very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to 
<1/1,000), very rare (<1/10,000), and not known (events not reported in registration trials cannot be estimated from post-marketing 
spontaneous reports). Very common: Headache. Common: Dizziness, flushing, dyspepsia, nasal congestion, back pain, myalgia. 
Uncommon: Hypersensitivity reactions, blurred vision, sensations described as eye pain, tachycardia, palpitations, hypotension 
(more commonly reported when tadalafil is given to patients who are already taking antihypertensive agents), hypertension, 
abdominal pain, gastro-oesophageal reflux, rash, hyperhidrosis (sweating), chest pain(1). Rare: Stroke(1) (including haemorrhagic 
events), syncope, transient ischaemic attacks(1), migraine(3), visual field defect, swelling of eyelids, conjunctival hyperaemia, 
myocardial infarction, urticaria, Stevens-Johnson syndrome(3), exfoliative dermatitis(3), prolonged erections, priapism(3), facial 
oedema(3), seizures, transient amnesia, NAION(3), retinal vascular occlusion(3), sudden hearing loss(2), unstable angina pectoris(3), 
ventricular arrhythmia(3), epistaxis, sudden cardiac death(1, 3). (1)Most of the patients in whom these events have been reported had 
pre-existing cardiovascular risk factors. (2)Sudden decrease or loss of hearing has been reported in a small number of post-
marketing and clinical trial cases with the use of all PDE5 inhibitors, including tadalafil. (3)Post-marketing surveillance reported 
adverse reactions not observed in placebo-controlled clinical trials. Adverse reactions reported with tadalafil were transient, and 
generally mild or moderate.  Adverse reaction data are limited in patients >75 years. A slightly higher incidence of ECG abnormalities, 
primarily sinus bradycardia, has been reported in patients treated with tadalafil once a day as compared with placebo.  Most of 
these ECG abnormalities were not associated with adverse reactions. For full details of these and other side-effects, please see the 
Summary of Product Characteristics, which is available at http://www.medicines.ie/. Legal Category POM Marketing 
Authorisation Numbers and Holder EU/1/02/237/001 EU/1/02/237/002 EU/1/02/237/003 EU/1/02/237/004 EU/1/02/237/005 
EU/1/02/237/006 EU/1/02/237/007 EU/1/02/237/008. Eli Lilly Nederland BV, Grootslag 1-5 3991, RA Houten, The Netherlands. 
Date of Preparation or Last Review March 2011. Full Prescribing Information is Available From Eli Lilly and Company Limited 
Lilly House, Priestley Road Basingstoke, Hampshire, RG24 9NL. Telephone: Basingstoke (01256) 315 000 E-mail: ukmedinfo@lilly.
com or Eli Lilly and Company (Ireland) Limited Hyde House, 65 Adelaide Road, Dublin 2, Republic of Ireland. Telephone: Dublin (01) 
661 4377. E-mail: ukmedinfo@lilly.com. *CIALIS (tadalafil) is a trademark of Eli Lilly and Company. Date of Preparation: September 
2010. Date of Revision: March 2011. References: 1. Cialis Summary of Product Characteristics. 2. Dean, J. et al. Psychosocial 
outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile 
dysfunction: Results of a multicenter, randomised, open label, crossover study. J Sex Med, 2006; 3:650-661. IECLS00172
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pharmacology and 
practice
Dr Martin Henman,  
Senior Lecturer at the School of 
Pharmacy in Trinity College
The panel presentation was 
opened by Dr Martin Henman, 
Senior lecturer at the School 
of Pharmacy in Trinity 
College who discussed the 
pharmacology of emergency 
hormonal contraception. 
As part of this presentation, 
Dr Henman discussed the 
background of emergency 
hormonal contraception, the 
indications of norlevo and the 
mechanism of such contracep-
tion both before and after 
ovulation. 
Continuing, he discussed 
the various reasons for using 
emergency contraception 
which include failure of the 
barrier or hormonal method; 
being forced to have sex; 
sexual assault; and the risk of 
conception when a person has 
been to avoid sexual inter-
course such as when taking 
teratogenic drugs. 
Dr Henman went on to point 
out how the pharmacist needs 
to gather information and 
assess the appropriateness of 
dispensing emergency hormo-
nal contraception before do-
ing so. As part of this process, 
he said pharmacists should 
establish the patient's reason 
for seeking the contraception, 
establish the timing of the 
unprotected sex and ask if it 
is within 72 hours of seeking 
contraception, look at the 
patients age and ask if it is ap-
propriate to dispense the drug, 
assess if the patient is already 
pregnant, if they have used 
another emergency contracep-
tion during this cycle and if 
they may have any allergies to 
progesterone.
Dr Henman went on to point 
out the contraindications and 
cautions associated with emer-
gency hormonal contracep-
tion and said that pharmacists 
need to be aware if there is 
hypersensitivity to any ingre-
dient, hepatic dysfunction, 
salpingitis or breast cancer 
amongst other problems.  He 
also said that pharmacists 
need to take heed that some 
drugs may interact with the 
contraception including St 
John’s Wort and that any pa-
tients taking warfarin should 
have their InR measured three 
days after taking the pill. 
He said that pharmacists 
must also advise nursing 
mothers to skip breast-feeding 
for a minimum of eight hours 
after taking the emergency 
contraceptive.
Concluding, Dr Henman 
discussed the uses of the drug 
and its efficacy as well as the 
few side effects of emergency 
contraception, which may 
include vomiting, diarrhoea 
and delayed menses. 
Irish Family planning 
Experience 
Dr Caitriona Henchion,  
Medical Director of the Irish 
Family Planning Association
Following on from Dr 
Henman’s presentation, Dr 
Caitriona Henchion, Medical 
Director of the Irish Family 
Planning Association (IFPA) 
discussed the experience 
of IFPA in dealing with 
emergency contraception. 
Opening her presentation, 
Dr Henchion discussed how 
the IFPA undertake their as-
sessments of patients before 
providing emergency hormo-
nal contraception to them. 
She said that it is imperative 
that in each case the medical 
professional involved finds 
out the date of the patients 
last period and assesses if this 
was normal, the date of the 
unprotected sex, any problems 
with emergency contraception 
and the patient's emergency 
contraception. 
Dr Henchion said that it is 
very important that pharma-
cists assess the time of the 
unprotected sex.
Continuing, Dr Henchion 
said that from her experience, 
it is very important that phar-
macists remind patients that 
if they do get bleeding soon 
after, this is just a withdrawal 
bleed and not a period and 
that they also need to make it 
clear that emergency hor-
monal contraception will not 
protect them from becoming 
pregnant for the rest of the 
cycle. 
Dr Henchion said that 
pharmacists also have an 
opportunity during this or 
any subsequent consultations 
to be proactive in providing 
information about the various 
contraception options open 
to them especially to women 
who might have difficulty in 
remembering to take the pill 
or pre-menopausal women 
who suffer from vaginal dry-
ness and find that condoms 
regularly rupture.
In terms of follow up, the 
IFPA director said that if the 
patient feels that everything is 
fine and their cycle returns to 
normal, that it should still be 
recommended to the patient 
that they check for sexually 
transmitted diseases and if 
their period is particularly light 
or heavy they should take a 
pregnancy test. 
Continuing, Dr Henchion 
discussed the issue of age of 
consent, which she agreed 
was presenting a significant 
dilemma to doctors and phar-
macists. 
She cited the UK’s Fraser 
guidelines which look spe-
cifically at whether doctors 
should be able to give contra-
ceptive advice or treatment 
to under 16-year-olds without 
parental consent and said that 
while these guidelines had 
not been tested in Ireland and 
offer no legal protection to 
pharmacists, they may be of 
use to pharmacists. 
These guidelines allow for 
doctors in the UK to provide 
contraceptive advice and treat-
ment to under -16s, without 
parental consent, if the profes-
sional is satisfied that the 
young person will understand 
their advice, cannot be per-
suaded to inform their parents, 
is likely to begin, or to continue 
having, sexual intercourse with 
or without contraceptive treat-
ment and the young person’s 
best interests require them to 
receive contraceptive advice 
or treatment with or without 
parental consent.
Dr Henchion pointed to 
a specific case study where 
they had provided emergency 
contraception to a 15-year-old. 
The next day the teen’s mother 
contacted the office to find out 
why her daughter had been 
given the pill. The receptionist 
explained that she could not 
give out any patient informa-
tion and that the woman could 
come in with her daughter to 
discuss the case. The mother 
came straight in with her 
daughter at which time it 
emerged that the girl was 
actually 14. When they came 
in the doctor went through 
her full consultation notes and 
discussed all the information 
she had gathered. In the end, 
Dr Henchion said the mother 
was actually pleased that her 
daughter had been given such 
a thorough assessment before 
being provided with the emer-
gency contraception. 
the International 
Experience EhC
John Stanley,  
Fellow at the School of 
Pharmacy, University of 
Hertfordshire and previous CEO 
Essex LPC
Following on from Dr 
Henman and Dr Henchion’s 
presentations, John Stanley, 
Fellow at the School of 
Pharmacy, University of 
Hertfordshire and previous 
CEO Essex lPC took to the 
floor to discuss what the UK 
has learned from emergency 
hormonal contraception over 
the past ten years since it first 
became available over the 
counter. 
Mr Stanley pointed out that 
the availability of emergency 
the Changing role of pharmacy in Ireland; 
Emergency Contraception 
Westin hotel, dublin on April 5, 2011
hosted by Allphar Services and hrA pharma 
Pharmacists from across the east of the country attended a special education 
evening in Dublin recently looking at emergency hormonal contraception. 
The event was organised by HRA Pharma following from the Irish Medicines 
Board (IMB) decision to grant their oral emergency contraceptive pill, norlevo 
(levonorgestrel 1.5mg) non-prescription status earlier this year.
Hosted in conjunction with AllPhar Services, the education meeting sought to 
raise awareness of how pharmacists’ practices will need to evolve so that women 
seeking emergency contraception from their pharmacy can be offered appropri-
ate professional support. 
The meeting was opened by Tony Fraser, General Manager for HRA Pharma in 
Ireland and over the course of the evening pharmacists were presented with the 
latest information and experiences relating to emergency hormonal contraception 
by a panel of expert speakers which included Dr Martin Henman, Senior lecturer 
at the School of Pharmacy in Trinity College, Dr Caitriona Henchion, Medical Direc-
tor of the Irish Family Planning Association and John Stanley, Fellow at the School 
of Pharmacy, University of Hertfordshire and previous CEO Essex lPC. 
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contraception is very widespread 
not just in the UK, but across the 
world and that recent research has 
shown that 40 per cent of young 
people have used emergency hor-
monal contraception at some stage. 
Mr Stanley said that the move to 
make emergency contraception 
available over the counter was in 
essence; giving the pharmacist “an-
other tool in the toolkit” ad he said 
that pharmacist  should work to cre-
ate awareness that they are offering 
this service. While he admitted that 
this may not be easy, he suggested 
perhaps that pharmacists build 
awareness of the service in the same 
way they make patients aware that 
they are participating in substance 
misuse programmes. 
He said that first and foremost, 
the pharmacists must ensure that 
they begin offering a truly profes-
sional service. “Pharmacists need 
to put themselves in the position of 
the patient. What we don’t want to 
create is a service where the patient 
feels judged or uncomfortable. We 
need to move to a more profes-
sional consultation.
“The professional consultation is 
not something which people always 
expect in pharmacy. likewise, some 
people expect to pull up outside 
on the double yellow line and want 
their prescription and toothpaste 
quickly. The patient needs to realize 
this is different. This is a professional 
service and it will take time,” he said. 
When considering how to de-
velop this service as a ‘professional 
service’, Mr Stanley said that phar-
macists will need to consider the 
time involved in the consultation, 
creating a confidential and personal 
consultation and the cost that this 
service will involve. 
He said that it is also worthwhile 
that pharmacists consider if they are 
going to use paperwork or some 
form of guidance form when distrib-
uting the emergency contraception 
pill. He said that having used such 
a form in the UK for a number of 
years, it has been agreed that such 
a form can help the pharmacist 
provide a better service whilst also 
helping them to decided if the 
emergency contraception should be 
dispensed. He said that pharmacists 
should also work to make more use 
of their consultation rooms which 
would also assist them in creating a 
more professional service overall. 
Concluding, Mr Stanley dis-
cussed the various ways in which 
pharmacists can help to improve 
their services during and after the 
consultation by providing signpost-
ing ad advice about other services. 
He said that this would help the 
profession in Ireland to move 
further in the direction of providing 
increased professional services to 
their patients. 
discussion 
Following from the presentations 
by the expert panel, the floor was 
opened to questions from the 
audience. A number of key issues 
arose during this session which 
were addressed by the expert panel 
including what to do when supply 
is not appropriate, what to do if 
emergency contraception fail- is 
the pharmacist liable, what to do 
if a parent contacts the pharmacy 
looking for information about their 
child and the differences between 
the age of medical consent and 
sexual consent. 
Follow up and further 
meetings 
Following on from the meeting, 
Tony Fraser, General Manager for 
HRA Pharma in Ireland said that 
he, along with Allphar Services, 
was delighted to have hosted this 
educational evening. Mr Fraser 
said that he firmly believes that it is 
vitally important that pharmacists 
are armed with the most current 
information available when offering 
women the help and advice they 
need to manage their overall sexual 
and reproductive health adding, 
“we believe that our event went a 
long way to ensuring that this is the 
case and we hope to hold more in 
the future”. 
Pamela logan, Director of Phar-
macy Services at the Irish Pharmacy 
Union added, “Recent develop-
ments mean that pharmacists will 
now take on the new responsibil-
ity of informing and advising the 
women who require this form of 
emergency contraception. The IPU, 
with the support of HRA Pharma, 
has already sent an education pack 
to all pharmacies in Ireland which 
complements the guidelines previ-
ously produced by the Pharmaceuti-
cal Society of Ireland, the Pharmacy 
Regulator. The fact that the HRA 
Pharma event had such fantastic 
support is encouraging and means 
that attendees will now feel better 
prepared dealing with this health-
care issue.”  
A number of similar educational 
events are set to take place around 
the country over the coming weeks. 
Postgraduate Diploma/M.Sc.
in Community Pharmacy
Applications are invited for admission to the postgraduate
Diploma/M. Sc. in Community Pharmacy in Trinity College
Dublin. This course has been specifically designed to meet the
needs of community pharmacists practising in Ireland and also
complies fully with the recommendations for specialist
community pharmacy courses issued by the EU Advisory
Committee on Pharmaceutical Training. Because of its distance-
learning format, participants can continue in full-time
employment throughout the course.
The course is intended to help community pharmacists to:
• develop their clinical, managerial and research skills;
• fulfil continuing professional development obligations under
the Pharmacy Act 2007;
• meet duties imposed by the HSE contract;
• undertake the role of a supervising pharmacist or
superintendent pharmacist with confidence;
• extend their professional role;
• contribute to patient care as part of the primary health care
team.
Course structure
The diploma and M.Sc. have core material in common.
Participants initially enter at diploma level, and on successful
completion of the common material they may choose either to
graduate with a Diploma in Community Pharmacy or to apply
for transfer to the M.Sc. in Community Pharmacy.
Both courses are available on a part-time basis, the diploma
being conducted over two years with one additional year for
students who progress to the M.Sc. In both courses participants
undertake a series of modules covering clinical, social and
business aspects of pharmacy practice, with opportunities for
specialisation in particular fields. Pharmacists who advance to
M.Sc. level undertake an additional module on research
methods and perform a research project relevant to community
pharmacy practice.
Entry requirements
Applicants must:
• be registered (or entitled to registration) as a pharmacist
with the Pharmaceutical Society of Ireland;
• work on a regular basis (full/part-time) in community
pharmacy.
Additional information from:
Address Diploma/M.Sc. in Community
Pharmacy, School of Pharmacy and
Pharmaceutical Sciences, Trinity College,
Dublin 2.
Telephone 01 896 3736 (Monday and Wednesday
9.15am-5pm, 
Thursday 9.15am-12 45pm)
Fax 01 896 2524
E-mail community.pharmacy@tcd.ie
Online applications to: www.pac.ie
For the course commencing in September
2011, the closing date for applications is 
30th June 2011.
Dr Martin Henman, Senior lecturer 
at the School of Pharmacy in Trinity 
College
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Gary Finnegan,
European Correspondent and Irish 
winner of 2009 and 2010 EU Health 
Prize for Journalists
patients lobby MEps on eye drug
Details of clinical trials taking 
place in the EU, Iceland, 
liechtenstein and norway 
will now be available online 
in a publicly accessible 
database. 
The EU Clinical Trials 
Register also allows 
the public to search for 
information on clinical trials 
authorised outside the EU 
if these studies are part of a 
paediatric investigation plan. 
lise Murphy, co-chair 
of the EMA’s Working 
Party with Patients’ and 
Consumers’ Organisations, 
said the move would 
increase transparency 
and help patients to find 
information on relevant 
clinical research. 
The database gives details 
of the sponsor and location 
of clinical trials as well the 
opinion of the relevant 
ethics committee. 
www.clinicaltrialsregister.
eu 
EMA limits ex-director 
Eu herbal medicines law under fire
A leading patient organisa-
tion has written to MEPs 
urging them to address safety 
concerns arising from the use 
of a cancer drug in treating 
age-related macular degenera-
tion (AMD). 
In a letter seen by Irish 
Pharmacist, Fighting Blindness 
said Irish hospitals are using 
Avastin to treat wet AMD even 
though it is not licensed for 
this purpose. The rationale for 
choosing to use this drug off-
label is that it is considerably 
cheaper than a similar medica-
tion, lucentis, which has been 
approved for AMD. 
lucentis comes in single-use 
sterile doses whereas Avas-
tin normally comes in larger 
volumes and is designed to be 
given intravenously to cancer 
patients. 
Some hospital pharmacists 
have been asked to prepare 
smaller doses of Avastin for 
ophthalmic use, while in other 
cases this is done by wholesal-
ers who sell it on to clinics – a 
practice that could bring infec-
tion risks for AMD patients.
The use of medicines for 
purposes other than those for 
which they are licensed is not 
uncommon and is permitted 
provided doctors believe there 
is a clinical justification for 
doing so. 
However, former European 
Medicines Agency chief Tho-
mas lonngren sparked a fierce 
debate on the subject last year 
before leaving his position 
as head of the EU regulator, 
claiming that cost-effective-
ness was the chief driver of the 
decision to use Avastin over 
lucentis. 
This is the line taken by 
Fighting Blindness in its letter 
to Irish MEPs, claiming that 
hospitals were acting primarily 
in the interest of their balance 
sheets. 
“We are aware of course 
that off-label therapies are 
often used in the treatment of 
chronic disease where there is 
no alternative. However, in this 
case a fully licensed therapy 
that has been through the 
regulatory process is not being 
used in favour of a therapy 
that has not been through this 
same process,” said Avril Daly, 
CEO of Fighting Blindness. 
She said her concern is 
“solely the implication of these 
decisions by hospital manag-
ers on patient safety and in the 
reporting of adverse affects”, 
adding that the move could 
undermine the established 
regulatory and licensing 
process which guarantees the 
safety and efficacy of medica-
tions. 
To date the Irish Medicines 
Board has received 10 reports 
of suspected adverse reactions 
associated with the ophthal-
mic use of Avastin, including 
reports of infection and haem-
orrhage. 
A Europe-wide ban on 
unregistered herbal medicines 
came into force this month but 
campaigners are threatening 
to take court action to have 
the law overturned. 
The directive on traditional 
herbal medicines was 
introduced in 2004 and 
required that all products 
obtain a formal authorisation 
by the end of April 2011. 
Once this transitional period 
expired, unauthorised herbal 
medicines can no longer be 
sold online, in pharmacies or in 
natural health shops. 
Industry campaigners are 
preparing a legal challenge 
at the High Court in london 
and have threatened to take a 
case to the European Court of 
Justice in luxembourg as part 
of their efforts to reverse the 
new rules. 
Dr Robert Verkerk, executive 
and scientific director of 
the Alliance for natural 
Health said the European 
directive is “disproportionate, 
non-transparent and 
discriminatory”, adding that 
the law has been interpreted 
differently across the 27 EU 
member states. 
The netherlands, for 
example, classifies some 
herbal remedies as foodstuffs 
meaning they are exempt from 
the new regulation, while the 
UK and Belgian authorities 
have taken a harder line, 
which will lead to hundreds 
of products being withdrawn 
from the shelves. 
Irish MEP Marian Harkin, 
who has campaigned on 
behalf of alternative remedies, 
said many treatments will 
“disappear” as a result of the 
directive and she questioned 
whether it was fair to assess 
traditional medicines using 
pharmaceutical techniques. 
The European Medicines 
Agency (EMA) has published 
strict new rules to curb the 
commercial activities of its 
former executive director in a 
bid to quell a storm of criticism 
from MEPs and transparency 
groups. 
Thomas lonngren, who 
left the top job at Europe’s 
regulator at the end of last 
year, has continued to work in 
the healthcare sector. The EMA 
has now completed a review 
Mr lonngren’s activities and 
said it could find no conflicts 
of interest. 
However, the london-
based regulator said it would 
enforce new rules to ensure 
its former director has no 
professional contact with EMA 
staff for two years. He is also 
prohibited from providing 
product-related advice to 
pharmaceutical companies. 
In a statement, the Agency 
criticised Mr lonngren 
for providing it with “late 
notification” about his new 
work. He had provided a 
letter in the days before his 
departure stating that he 
intended to use his experience 
in the health and medicine 
sector to provide “advice and 
counsel to the pharmaceutical 
industry”. 
He added that he was “very 
conscious” of his obligations 
to the EMA and assured his 
former employer that his new 
role would not constitute a 
conflict of interest. 
EMA chairman Pat 
O’Mahony had originally 
accepted lonngren’s 
assurances in writing in 
January, but the Agency was 
forced to conduct a more 
rigorous investigation by 
MEPs. 
Marian harkin, MEp
New Eu 
clinical trials 
database 
goes live 
45
If only I could 
fi nd the 
words
Communication is important1-3
Abbreviated Prescribing Information: For full prescribing information refer to the Summary of Product Characteristics. 
Name: Ebixa. Active Substance: Memantine Hydrochloride. Indication: Treatment of patients with moderate to severe 
Alzheimer’s disease. Dosage & Administration: Treatment should be initiated and supervised by a physician experienced 
in the diagnosis and treatment of Alzheimer’s dementia.  Therapy should only be started if a caregiver is available who 
will regularly monitor the intake of the medicinal product by the patient.  Treatment is orally either as tablets (10 mg) or 
solution (5mg/pump) taken with or without food at the same time every day.  The solution should only be dosed onto a 
spoon or into a glass of water using the pump.  Maintenance dose is 20mg/day, (two tablets or 2ml solution [4 downward 
pumps] once daily). Treatment starts with 5mg/day (half a tablet or 0.5 ml solution [1 downward pump] once  daily) for the 
fi rst week; the 2nd week 10mg/day (one tablet or 1 ml solution [2 downward pumps] once daily); the 3rd week 15mg/day 
(one and a half tablets or 1.5ml solution [3 downward pumps] once daily) and the 4th week 20mg/day (two tablets or 2ml 
solution [4 downward pumps] once daily). Moderate renal impairment 10mg/day (one tablet or 1 ml solution [2 downward 
pumps] once daily), if well tolerated after 7 days the dose can be titrated up to 20mg/day (two tablets or 2 ml solution [4 
downward pumps] once daily). Severe renal impairment- dose is 10 mg/day (one tablet or 1 ml solution [2 downward pumps] 
once daily). Mild-moderate hepatic impairment- no dose adjustment.  Severe hepatic impairment- no data available: Not 
recommended.  Children & Adolescents: Not recommended. Contraindications: Hypersensitivity to the active substance or 
any of the excipients. Pregnancy and Lactation: Pregnancy: Memantine should not be used in pregnant women unless clearly 
necessary. Lactation: Memantine should not be used in women who are breastfeeding. Special Warnings and Precautions for 
use: Caution is recommended in patients with epilepsy. Caution is advised in patients with raised urine pH as this may elevate 
plasma levels. Clinical trial data are limited on patients with recent myocardial infarction, uncompensated congestive heart 
failure and uncontrolled hypertension and patients with these conditions should be closely supervised. Avoid concomitant use 
of NMDA antagonists (see also interactions). Oral solution only: Patients with rare hereditary problems of fructose intolerance 
should not take Ebixa 5mg/pump oral solution as it contains sorbitol. Tablets are lactose free.  Patients should be warned to 
take special care if driving and using machines as Ebixa has minor to moderate infl uence on these tasks.  Interactions: Effects 
of L-Dopa, dopaminergic agonists and anticholinergics may be enhanced. Effects of barbiturates and neuroleptics may be 
reduced. Concomitant administration of Ebixa with antispasmodic agents e.g. dantrolene and baclofen can modify their effects, 
dose adjustments may be necessary. Increased plasma levels could occur with concomitant use of cimetidine, ranitidine, 
procainamide, quinidine, quinine and nicotine.  Co-administration with hydrochlorothiazide (HCT) may lead to a reduced 
serum level of HCT. Concomitant use of NMDA antagonist- amantadine, ketamine, dextromethorphan or phenytoin should be 
avoided. Close monitoring of prothrombin time or INR is advisable for patients treated concomitantly with oral anticoagulants. 
Adverse reactions: Common (≥1/100 to <1/10) headache, somnolence, hypertension, constipation, dizziness, dyspnoea 
and drug hypersensitivity. Uncommon reactions (≥1/1,000 to <1/100): cardiac failure, fatigue, fungal infections, confusion, 
hallucinations (mainly in severe Alzheimer’s disease), venous thrombosis/thromboembolism, vomiting, gait abnormal. Very rare 
(<1/10,000): seizures. Not known: Isolated cases of pancreatitis and psychotic reactions have been reported post-marketing. 
Alzheimer’s disease has been associated with depression, suicidal ideation and suicide. In post-marketing experience these 
events have been reported in patients treated with memantine. Overdose: Symptomatic treatment. Elimination: Mainly 
in unchanged form via the kidneys. Legal Category: POM.  Marketing Authorisation Holder: H.Lundbeck A/S, Ottiliavej 9, 
DK-2500 Valby, Denmark. Marketing Authorisation Numbers: EU/1/02/219/005 Ebixa 5mg/pump oral solution-50ml bottle. 
EU/1/02/219/006 Ebixa 5mg/pump oral solution-100ml bottle. EU/1/02/219/007 Ebixa fi lm-coated tablets 10mg, 28 pack 
size. EU/1/02/219/008 Ebixa fi lm-coated tablets 10mg, 56 pack size. Further information may be obtained from: Lundbeck 
(Ireland) Ltd., 7 Riverwalk, Citywest Business Campus, Dublin 24.
Date of Preparation: January 2011
References: 1. Ferris et al. 2009. Alzheimer’s & Dementia 5;369-374. 2. Emre et al. 2008. Journal of Alzheimer’s Disease 14;193-
199. 3. Hofbauer et al. 2009. Presented at the 12th Intl. Conference on Alzheimer’s Disease. July 11-16. 4. Claxton et al. 2001. 
Clinical Therapeutics. 23;1296-1310. 5. Ebixa Summary of Product Characteristics.
Some studies include patients stable on acetylcholinesterase inhibitors.
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phArmAcY AwArds
And the nominations are open…
pictured at the official launch of the helix health Irish pharmacist Awards, 
in association with the Benevolent trust Fund of the pharmaceutical 
Society of Ireland, are (right) Bonnie Conlan and Alex Nevin, (left) Fintan 
Moore, Chairperson, Awards Committee and howard Beggs, CEo, helix 
health and (Bottom) tom Mcdonald, JpA Brenson lawlor, rebecca garland, 
Activas Ireland, Jeffrey Walsh, pinewood healthcare, Sarah Corry, teva 
Ireland, howard Beggs, CEo helicx health,  donna Murphy, pinewood 
healthcare, Fintan Moore, Chairperson, Awards Committee.
this year’s awards will 
recognise the contribution 
of the pharmacy 
profession in healthcare 
as well as celebrating 
excellence amongst 
pharmacists. 
Nominations for this 
year’s awards will open 
this May with the gala 
awards ceremony-taking 
place at the Mansion 
house on Saturday, 
November 12th 2011. 
For further information 
on the awards please 
contact Fintan Moore 
at fm.gpp22@topmail.
ie  or Aisling reast at 
reast@eircom.net, John 
Bourke at jbourke@
castlemartincare.
com or Cicely roche at 
cicelyroche@eircom.net.
Irish Pharmacist is 
delighted to support this 
event as official media 
sponsors. 
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Abbreviated Prescribing Information: For full prescribing information refer to the Summary of Product Characteristics. Name: 
Ebixa Active Substance: Memantine Hydrochloride. Indication: Treatment of patients with moderate to severe Alzheimer’s 
disease. Dosage & Administration: Treatment should be initiated and supervised by a physician experienced in the diagnosis 
and treatment of Alzheimer’s dementia.  Therapy should only be started if a caregiver is available who will regularly monitor the 
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W
hen the Centre for Ageing 
Research and Development 
(CARDI) released a new 
report last month (April 
2011) which highlighted 
a significant potential of 
inappropriate prescribing in nursing homes in 
Ireland, concerns were voiced not only about 
the impact that this could have on vulnerable 
patients, but also on the state’s coffers. 
The report “An Evaluation of the inappropriate 
prescribing in older residents in long term care 
facilities in the greater Cork and Northern Ireland 
regions using the STOPP and Beers’ criteria” found 
that 73 per cent of nursing home residents in 
the Republic of Ireland were receiving “at least 
one potentially inappropriate medicine,” while 
in northern Ireland, 67 per cent of those in the 
sample were receiving a potentially inappropriate 
medicine.
It detailed how 630 older people in long term 
care in northern Ireland and in the Republic 
of Ireland, who were surveyed as part of the 
research, were receiving an average of 11 
medicines each and half of these people were 
prescribed eight to 14 daily medicines each. 
The report also highlighted a number of areas 
of prescribing concern, for example, the long-
term use of both benzodiazepines and hypnotics, 
in older residents residing in long-term care 
facilities. 
Meanwhile, the cost of the inappropriate 
medicines was valued at €170 per older person 
in the northern Ireland sample and €356 per 
person in the Republic of Ireland sample. 
Can Murs solve the problem? 
Following the publication of the report, a number 
of recommendations were made, which the 
report’s researchers believe, could help to reduce 
potential inappropriate prescribing including 
the introduction of protocol driven medication 
reviews. 
According to Dr Stephen Byrne, Senior lecturer 
in Clinical Pharmacy at University College 
Cork and lead researcher on the CARDI report, 
introducing such reviews would ensure that 
pharmacists, GPs, consultants and nurses work 
closely with one another and with older people 
and their relatives to ensure patients receive the 
medicines they need. 
Asked how successful MURs and in particular, 
pharmacist led MURs might be, Dr Byrne 
admitted that while pharmacist led MURs have 
only proved successful to varying degrees in 
the UK and the US, where they are already in 
existence, and that they are somewhat time 
consuming, he believed these reviews could 
prove to be of great importance in polypharmacy 
and in cases involving more vulnerable patients. 
“Introducing pharmacist led medicine use 
reviews would allow the pharmacists to see 
all of the patient’s medicines and see what is 
being used and what is not being used. yes, it 
will involve the pharmacists having to remove 
him/herself from the dispensary for 30 minutes 
or so, but it will help him or her to identify 
compliance and non-compliance, usage issues 
as well as possible serious interactions. Of course 
there is also potential here to identify potential 
inappropriate medicines, particularly in patients 
who are vulnerable or taking a large number of 
medicines,” he said. 
Dr Byrne’s beliefs are shared by Irish Pharmacy 
Union (IPU) President, Darragh O’loughlin. “We’re 
absolutely confident that MURs wil have a real 
value for patients, not only in terms of looking 
at inappropriate medicines, but in making sure 
patients are taking the right medicines and 
in maybe looking at medicines that they are 
experiencing side effects from and substituting 
these drugs with new medicines instead of just 
treating the side effects of them,” he said. 
The IPU chief said the introduction of 
pharmacist led medicine use reviews would 
also help pharmacists identify where patients 
might not be taking medications which may be 
recommended for their profile. “Some patients 
are also not taking the medicines that they 
should be taking. A few years ago a decision 
was made that patients with diabetes should 
also be taking ace-inhibitors. By undertaking 
an MUR with a patient with diabetes, it would 
be very simple to see if they are taking all the 
medications, which have been recommended for 
them.The MURs will also give us the opportunity 
to establish where there might be other types 
of gaps in medication therapy. For example 
patients with osteoporosis are supposed to take 
the anti-osteoporosis drug biophosphonate, but 
they should also be taking calcium and vitamin D. 
We find in some cases these patients are taking 
calcium, but not taking the vitamin D needed to 
absorb this. An MUR would help to ensure that 
this does not continue to happen,” he said. 
pipedream or reality?
The reality of seeing MURs developed in Ireland is 
one that is very real indeed. 
Back in 2008, the Pharmacy Ireland 2020 
Working Group Report, recommended that 
“Medicine use review (MUR) is likely to be 
the most appropriate method for assessing 
compliance and improving medicines-taking 
through accordance.”
This report, is currently being progressed 
through the Pharmaceutical Society of Ireland 
(PSI) in a number of ways, and in particular 
through support of the work of the HSE Clinical 
Strategy and Programme’s Directorate under Dr 
Barry White. 
The PSI have reiterated that they believe 
“pharmacists have an essential role to play in 
ensuring the safe and rational use of medicines, 
which includes utilising their expertise in relation 
to therapeutic review and patient counseling”. 
last year, the regulatory body issued a practice 
notice to pharmacists in respect of patients 
in nursing homes/residential care settings 
specifically, which some might say, signaled the 
beginning of MURs. 
This document set out how “prior to the 
dispensing of each prescription, and prior to 
the supply of any medicinal product concerned, 
a registered pharmacist must review the 
prescription having regard to the pharmaceutical 
dr Stephen Byrne, Senior lecturer in 
Clinical pharmacy at university College 
Cork 
Murs: where 
are we now?
Following on from a new report which found that 
seven out of ten older people in nursing homes in 
Ireland are receiving at least one inappropriately 
prescribed medicine, Mary O’Keeffe asks if 
pharmacist led medicine use reviews (MURs) could 
help to address this serious problem and if so, how 
close we are to seeing MURs come to fruition. 
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and therapeutic appropriateness of the medicine 
therapy for the patient and the use by the patient 
of any other medicines etc. that the pharmacist is, 
or ought reasonably be, aware of.”
The Department of Health has also broadly, yet 
somewhat cautiously welcomed the introduction 
of pharmacist led MURs. 
Asked how the Minister for Health, Dr James 
Reilly might welcome the introduction of such 
a service, a spokesperson from the Department 
of Health said, “The Minister is generally 
supportive of an expanded role for pharmacists 
in the delivery of services at primary care level. 
Any such expansion of service should be cost 
effective, promote best use of healthcare 
resources, be evidence based, be part of a 
structured framework of patient care and 
demonstrate direct benefits to patients.”
the hSE pilot 
Following on from the PSI recommendations, 
last year the Health Service Executive (HSE) 
undertook a pilot MUR initiative with 13 Primary 
Care Teams across the country. 
This pilot, which involved 19 pharmacist-
primary care teams, aimed at looking at 
improving the inter-professional relationship 
between Primary Care Team members and local 
pharmacists to achieve a “greater good”.
Outlining details of the pilot study, a 
spokesperson for the HSE explained, “The 
aim of the programme is to improve the inter-
professional relationship between PCT members 
and local pharmacists and to improve patient 
outcome, compliance and reduce wastage. 
It is envisaged that the pilot will begin to 
demonstrate how the skills and expertise of 
community pharmacists can best be utilised 
within the Primary Care Team setting.”
As part of the initiative, pharmacists were 
aligned to a local PCT who undertook MURs 
with a number of patients. Once the patients 
were selected and agreed between the GP and 
the pharmacist (and patient consent obtained) 
the pharmacist arranged for the MUR to be 
conducted with the patient. 
A feedback form was provided to the GP 
and indicated a list of the medication that the 
patient was on and any issues or problems that 
the GP should be aware of, which is impacting 
on medication compliance. The feedback form 
recommended a consultation either urgently, 
routinely at next visit, or no action required. The 
pharmacist then followed up with a second MUR 
approximately two months later in order to allow 
evaluation of the initiative.
The MURs conducted under the pilot are 
currently being reviewed and evaluated by a 
Researcher in Trinity College and will be available 
in early Summer 2011. 
the logistics involved
While the Irish Pharmacy Union in general is very 
supportive of the introduction of medicine use 
reviews and has in fact, reiterated calls on the 
Minister for Health to implement proposals to 
introduce pharmacist led medicine use reviews 
for patients who are using multiple medications, 
the Galway based union president, Mr Darragh O’ 
loughlin admitted that some serious thought will 
need to be put into the development and roll-out 
of this service.
“When MURs are introduced, these will require 
a proper sit-down with the patient at a pre-
dictated time. It’s likely that the patient will need 
to make an appointment for this. I imagine that 
the whole process will take about 40 minutes; 20 
minutes to review the patient’s notes and make 
recommendations and 20 minutes to meet with 
the patient. We will need to look at how this can 
all best be done," he said. 
Of course payment and contracts will need 
to be discussed prior to the development and 
rollout of MURs here also. “There hasn’t been any 
discussion about payment yet. At this stage we’ve 
just done the pilot to see if it can be done and 
what resources it involves, but when the results 
do come out, we will look at what is involved in 
the MUR and how much time it takes and we will 
have to make sure to get a reasonsable payment 
for the work involved, otherwise it just won’t 
happen.”
look before you leap 
While from the outside, some might believe a 
blanket introduction of MURs might seem like 
a good idea, the reality is that pharmacist led 
medicine use reviews have not been without 
criticism and controversy in the countries where 
they have been implemented.
In England, where MURs were introduced in 
2005, one report undertaken for the national 
Institute for Health Research found tht MURs 
were “bordering on fraudulent” with pharmacists 
admitting to being paid for reviews which had 
limited value as it was found that GPs were often 
ignoring the results of the reports. 
That said, in the first audit of MURs in England, 
80 per cent of patients who took part in the audit 
said that their knowledge of medicines and how 
to use them had improved as a result of the MUR. 
In northern Ireland and Scotland, where similar 
review programmes were introduced through 
the Medicine Management Scheme and the 
Chronic Medications Service respectively, the 
response has been equally mixed. 
northen Ireland based pharmacist, Terry 
Maguire says that while the schemes are ideal on 
an aspirational level, that practically, they are just 
not working.
“Under the Medicine’s Management Scheme, 
which is a little different to England’s MUR 
Scheme, the pharmacist meets with patients and 
undertakes a medicines compliance assessment 
as well as assessing any side-effects or issues 
as a result of the medicines with the patient. 
Following on from this review, a report is sent to 
the GP.
“The main problem with the scheme is the fact 
that it is poorly resourced and is not featured 
in our contracts, albeit there is payment for 
the service. There has been a very poor take-
up of the scheme because of the fact that the 
documentation associated with it is turgid, 
GPs won’t sign the report forms and many 
pharmacists feel out of their depth doing the 
assessment.”
Concluding he added, “the ultimate end goal 
of community pharmacy is to improve patient 
outcomes and while we want to see pharmacy 
move on from a supply role to improving patient 
services, it is simply not easy to get to where 
the government wants us or indeed, where 
aspirationally, we want to be.”
Mr Maguire said that he was hopeful that 
the upcoming reviews and assessments of the 
medicine management schemes in northern 
Ireland might look at how to better ensure the 
development and provision of such schemes 
and that improvements might also be made to 
pharmacists’ contracts to ensure the continued 
development of the scheme.
When the results 
do come out, 
we will look at what is 
involved in the MUR and 
how much time it takes 
and we will have to make 
sure to get a reasonsable 
payment for the work 
involved, otherwise it 
just won’t happen.’
“
darragh o’loughlin, Ipu president  
terry Maguire, Northern Irish pharmacist
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dR dEs CORRIGAN
t
wo reports from the Health Research 
Board (HRB); the first dealing with 
drug-related deaths up to the end 
of 2008 and the other, a trend paper 
dealing with benzodiazepines 
(BZD), have put the spotlight on 
problematic use of prescribed drugs.
The most disturbing feature of the report from 
the national Drug Related Deaths Index (nDRDI) 
was that 524 such deaths were recorded in 2008. 
This is more than the number of those killed in 
road accidents yet we spend far more on road 
safety campaigns than we spend on preventing 
drug deaths. 
The other disturbing feature was the fact that 
most deaths from drug poisonings involved 
prescription drugs, chiefly benzodiazepines (38 
per cent), methadone (29 per cent) and anti-
depressant (21 per cent). 
Very few of these preventable deaths 
involved just one substance with mixtures of 
narcotic analgesics (heroin and/or methadone), 
benzodiazepines (BZDs) and alcohol involved in 
most of the 2,434 poisoning deaths since 1998. 
Other prescription drugs were found in 22 per 
cent of cases. This category included non-BZD 
sedatives, anti-psychotics and cardiovascular 
medicines. Incidentally non-opiate analgesics 
were linked to 17 deaths in 2008.
It is abundantly clear from the figures that the 
profession cannot escape playing a key role in 
preventing such deaths within the framework of 
the national overdose prevention strategy, which 
is at an advanced stage of development by an 
expert HSE group. It is also clear from the recently 
published Review of the Methadone Treatment 
Protocol that the PSI  has committed itself to 
playing its part especially in relation to improving 
BZD prescribing practices. Action in relation to 
BZDs is long overdue on the basis of the shocking 
nDRDI figures and on those from the national 
Drug Treatment Reporting System (nDTRS). In the 
years 2003 to 2008, the annual number of treated 
cases  reporting a BZD as a problem substance 
increased by 63 per cent from 1,054 to 1,719. 
Some of the cases involve BZD as the main 
problem drug and this was more likely outside 
of Dublin. On the other hand, where BZDs were 
reported as an additional problem substance, 
this was more likely to be in Dublin and to involve 
those whose main problem substance was an 
opiate. 
This ties in with the belief that there are two 
types of problem BZD users, namely, those who 
have developed dependent use as a result of long 
term medical use and those who are opiate-
dependent and who also use huge quantities 
of prescribed or black market tranquillisers. It is 
these latter individuals, using 20 or 30 tablets a 
day (which is not an exaggeration) who are most 
at risk of death.  In drawing attention to this risk 
I am open to an accusation of reinventing the 
wheel because the 2002 Benzodiazepine Report 
from the Dept. of Health and Children states that 
patients dependent on opioids should be advised 
that the taking of BZDs can greatly increase the risk 
of overdose. This message should be conveyed as 
a matter of  routine by all those who have contact 
with drug misusers. Included in that last sentence 
are staff in the 522 pharmacies who dispense 
methadone to the 5,615 patients (out of a total 
of 9,428 on the Central Treatment list). That 
represents a lot of opportunities for individual 
pharmacists to intervene and save lives.
That 2002 Report also stated unambiguously 
that  prescribing benzodiazepines to opioid users 
(and other drug users) should be seen as exceptional 
rather than a routine decision. For most of us 
involved in responding to problem drugtaking, 
it seems to be the other way round – that 
prescribing BZDs is the routine rather than the 
exception. Adherence to the DOHC advice would 
go a long way to reducing the death toll from 
drugs.
I have been pressing for some time for effective 
action in relation to the inappropriate prescribing 
of BZDs generally and more specifically to opiate 
users. It is clear from the General Population 
Drug Survey conducted by the nACD that there 
is leakage of prescribed BZDs and indeed 
other sedatives onto the black market. The 
2006/7 Survey revealed that 11 per 
cent of those who had used sedatives 
did not get them on prescription. 
Many got them from someone they 
knew and 3 per cent of women said they 
got them “in a chemist without 
a prescription”. If that is true 
then it represents a complete 
abandonment of professional 
ethics by those involved.
In order to reduce the diversion 
onto the black market and to 
reduce the level of problematic 
BZD use, we need to start 
by implementing the 
longstanding, simple and 
straightforward medical 
guidance. Doing so will make 
a huge difference. The BnF states 
that these valuable medicines 
should only be used for stress 
or insomnia, which is severe and 
disabling and that the lowest 
possible dose be prescribed 
for the shortest possible time; ie 
no more than two to four weeks. 
What could be more clearcut?
I suspect that the 
overwhelming reaction from many 
pharmacists will be concern for their 
many non-opiate using patients who 
have been prescribed BZDs for much 
longer than four weeks. Many of those 
will have to be maintained on their 
particular BZD because detoxification 
at this stage would be too difficult, 
unpleasant and the outcome uncertain. 
Where individuals wish to wean 
themselves off these drugs then there is 
the need for a structured care plan based 
on a partnership between the patient, 
their prescriber, their pharmacist and 
their family whose support during the 
lengthy tapered withdrawal and post-
withdrawal phases will be vital.
In the case of prescribing to opiate-
dependent individuals, bluntly this has to 
stop because it is costing too many lives.
There is a need to extend the existing 
audit of prescribing practices under the 
GMS to private prescriptions for BZDs. 
When I asked TCD pharmacy students 
about this at a recent seminar in their 
‘Addiction Pharmacy’ module, one of 
the suggestions was to use DPS returns. 
It may involve extra work, but if evidence of 
persistent clinically inappropriate prescribing 
can be identified then appropriate sanctions 
as envisaged in the 1977 Misuse of Drugs 
Act should be applied. The situation is that 
serious.
Putting the spotlight on our 
prescription drug problem
With new research showing that more people die as 
a result of drugs than road traffic collisions, Dr Des 
Corrigan asks what measures need to be taken to 
tackle this serious problem.
The most 
disturbing feature 
of the report from the 
national Drug Related 
Deaths Index (nDRDI) 
was that 524 such deaths 
were recorded in 2008. 
This is more than the 
number of those killed 
in road accidents yet we 
spend far more on road 
safety campaigns than 
we spend on preventing 
drug deaths.”
“
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Call us at 01 4429869 or email us at 
info@easysop.com to learn more about how 
we make it easy to get your SOPs
 Contact Us Now
“Trying to find the time to write SOPs as 
required by the PSI was a major problem 
until I discovered EasySOP. All the hassle 
was taken away at a price that was great 
value. I would recommend EasySOP to all” - 
Seán Meade, Meade’s Medical Hall, 
Carrick-on-Súir
“Fantastic value, I would highly recommend 
EasySOP” - Jarlath Philips, Flanagan’s 
Pharmacy, Headford
“... I would take EasySOP as being the best 
in the market in terms of cost, ease of use 
and specific to individual practice 
requirements” - Anne Marie Sorohan MPSI, 
Ferbane Pharmacy
“We have no hesitation in recommending 
this service to other Pharmacy owners”
- Michele Burke, Professional Affairs 
Co-ordinator, McSweeney Group
Testimonials
1. Dispensing
2. OTC Sale
3. Sourcing of medicines
4. Pharmacy Housekeeping
5. Staff Training
6. Error & Incident Management
7. Health Screening Services
8. Wide range of further additional services
Areas covered
1. Peace of mind: Our unique service will ensure 
that your pharmacy is equipped with all the SOPs 
needed to comply with PSI guidance and legislative 
requirements.
2. Quality: All SOPs are created based on PSI and 
IPU guidance in addition to feedback from 
community pharmacists.
3. Time: Free up your valuable time from having to 
research and write a long list of SOPs. Let us do the 
hard work!
Reasons to choose EasySOP
Get high quality, fully customisable Standard 
Operating Procedures (SOPs) for your pharmacy.
Just contact the SOP writing specialists at 
www.EasySOP.com
GET THEM FROM EASYSOP - THE SOP WRITING SPECIALISTS.
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ThE COAlFACEopinion
W
hen I prepared last month's 
article I mentioned that to 
my knowledge there has 
never been a manpower 
survey undertaken for Irish 
pharmacy. So in the light 
of the undoubted tough times facing this year’s 
crop of graduates I decided to delve a little 
deeper. 
My initial gut feeling was that we are qualifying 
too many new pharmacists. We have gone from 
an under-supply of new pharmacists about 20-25 
years ago to a massive oversupply. I think that 
we can all accept that the civil service, aka the 
hospital sector, will not be recruiting any extra 
staff, never mind pharmacists over the next few 
years. So where are the 180 or so new graduates 
to go? It already looks like that they will have a 
difficult time finding a pre-reg placement. Throw 
in the fact that most community pharmacies 
are in cutback mode rather than hiring mode 
at present and things are looking bleaker. 
And I haven’t even touched on the numbers 
of Irish students studying pharmacy in the UK 
presumably with intentions of returning home 
and establishing themselves here. 
dENMArK vErSuS IrElANd 
I decided to check to see how an equivalent 
European country handles this. Denmark has a 
similar population to Ireland. They have only one 
school of pharmacy. It does have 230 graduates 
per year but they estimate that only 15 per cent 
of these will go into community pharmacy. 
Another 20 per cent will go to hospital and 
the remainder will work in Denmark’s massive 
pharmaceutical manufacturing industry. That’s 
about 35 new community pharmacists per year 
and a further 45 or so for hospital. It’s a long way 
from 180. But then in Denmark, the government 
and the Danish equivalent of the IPU sit down 
every two years to agree a level of profitability 
for community pharmacy. That’s near to Utopia 
compared to the current Irish situation. 
So where are the pharmacy graduates of the 
last few years? Although the pharmacy degree 
leaves them amply qualified for a role in the 
pharmaceutical manufacturing industry it seems 
that few enough have sought their future there. 
My queries to date would seem to indicate 
that many of the last few years graduates now 
reside in the UK. And sadly it would appear that 
the return to emigration is the most promising 
option for many. The current batch of graduates 
were smart enough to get into pharmacy courses 
in a very competitive environment. They are also 
smart enough to see a basic economic tenet. As 
supply rises price falls. The more pharmacists 
around, the lower salaries will be. I have already 
seen a full time pharmacist position offered at a 
salary of €25,000 per annum, i.e. €12 per hour. 
While this position may not be typical it does 
represent a huge drop in salaries from just over 
two years ago. 
MoBIlIty 
This does not bode well for mobility in the 
pharmacy labour market. Just consider, if you 
are an employee pharmacist in a post where the 
salary was set during the boom times. How likely 
are you to move willingly to another post when 
the first thing you have to face is a significant 
drop in salary. From an employer point of view 
the surplus pharmacists has its attractions. Being 
able to take on new pharmacists at a lower salary 
definitely has some good points. But to my mind 
this raises questions as to the calibre of the next 
generation of pharmacists. Whatever about the 
intellectual challenge of pharmacy I cannot see 
the elite students seeing pharmacy as a bountiful 
career. However, if you are a pharmacist who 
has financed a second degree yourself then you 
are not going to hang around for this level of 
remuneration. Ryanair to Stansted is looking 
good. I cannot but wonder if this message 
will get through to the 500+ points cohort of 
students sitting for their leaving cert this year. 
If not I believe that this may be because all the 
talk about the drop in pharmacist prospects has 
been within the pharmacy sphere. If you are from 
outside of this milieu you would be forgiven for 
thinking that all was still rosy in pharmacy land. 
All this begs the question, should we as 
a nation be putting all the resources into 
training these future emigrant or unemployed 
pharmacists? I confess I don’t know the full cost 
of government funding for pharmacy places 
in the three colleges, but if there is no need 
for them wouldn’t the money be better spent 
training some other graduates? We as a nation 
could do with a new batch of economists and 
bankers. God knows the last lot haven’t served us 
too well. 
dEAFENINg SIlENCE 
To get information for this article I emailed 
several bodies: the PSI, the Departments of 
Education and Enterprise & Employment as 
well as the HEA. I asked them a few things. 
Firstly, if they were aware of any manpower 
studies in relation to community pharmacy 
and the replacement rates necessary? I also 
asked the HEA and Department of Education 
were there any plans to change the number of 
places funded in pharmacy in the light of the 
current downturn.? And how have our overlords 
responded to this? The Department of Education 
referred me to the HEA and the Department of 
Employment referred me to the PSI. As for the 
PSI and the HEA the silence has been deafening. 
There are a number of issues for a regulator in 
this type of situation. Unemployed pharmacists 
are non-practising pharmacists. How might 
they be expected to keep their skill levels up? 
Similarly for pharmacists who decide to work in 
the manufacturing industry for a spell. How long 
do they have to be away from community before 
it may be necessary for them to undergo a period 
of re-acquainting themselves before being 
allowed to practice in community again? I am 
not aware of any current regulation, which would 
deal with this type of situation. Certainly they 
will need three years of community experience 
before they could operate as a supervising 
pharmacist, but nothing about operating as a 
regular Joe Soap pharmacist. Has Ambrose made 
any approaches to government to change or 
produce new regulations? not that I have heard 
of. 
As for the current batch of pharmacy students. 
What advice do I have for them? Seek out a 
career in the manufacturing sector or prepare for 
emigration. And as for those sitting the leaving 
cert this year, if you decide that you really want 
to be a community pharmacist then do it for the 
love of pharmacy. 
From an employer 
point of view the 
surplus of pharmacists 
has its attractions. Being 
able to take on new 
pharmacists at a lower 
salary definitely has 
some good points.”
dAvId jORdAN
David Jordan has worked 
in community pharmacy 
since 1979, qualifying as 
a pharmacist in 1983. He 
was chairperson of the 
Community Employee 
Committee of the IPU from 
1990 to 1998 and treasurer 
from 1994 to 1996. His 
main stress relief is riding 
his motorbike with his 
friends from 
www.irishbikerforum.com
“
Where is the 
manpower?
Disillusioned and bewildered by the challenges 
facing pharmacy graduates, David Jordan asks 
where the manpower survey is for Irish pharmacy?
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emergency hormonal contraception. 
To help you and your customers,
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Adverse events should be reported. Reporting forms 
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med.info.ie@hra-pharma.com
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Not recommended with severe hepatic dysfunction. The product
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of galactose intolerance, Lapp lactase deficiency or glucose-galactose
malabsorption should not take this medicine. Interactions: Metabolism
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opinion vIEw FROM AbOvE
Terry Maguire owns two 
pharmacies in Belfast. 
He is an honorary 
senior lecturer at the 
School of Pharmacy, 
the Queen’s University 
of Belfast. His research 
interests include 
the contribution of 
community pharmacy 
to improving public 
health.
TERRy MAGUIRE
I 
can’t be sure if it was my book “The Obesity 
Epidemic”, my article “The No Bulls**t Diet” 
(which was printed in the January edition of 
Irish Pharmacist) or my negative commen-
tary on Stephen nolan’s journalistic skills in 
“Bad News” (printed in the March edition of 
Irish Pharmacist) but, something triggered the 
invitation to work with the Stephen Nolan Show 
on a hard hitting TV documentary about obesity; 
its causes and its health impact. Stephen nolan is 
northern Ireland’s answer to Gerry Ryan but twice 
the size. 
By the way my book has now sold a total of 77 
copies worldwide and I have kept the cheque for 
£77.00 framed on my pharmacy wall as proof – not 
worth cashing it as I will be forced to pay VAT at 20 
per cent (I’m personally registered) and income 
tax at 40 per cent, which makes £36. It will serve as 
a reminder to me never ever again to write a book. 
Anyway, I was proud, verging on conceit, to be 
appointed consultant (unpaid) to the programme 
advising Stephen and his staff on obesity man-
agement; the role of bariatric surgery, successful 
behavioural interventions, drugs and even bad fad 
diets. 
The programme, broadcast at the beginning of 
April, was a great success, hard hitting with wide 
impact. Stephen attended a fat person’s autopsy 
where he splashed around in litres of bright yel-
low visceral and subcutaneous fat – I suggested 
adipose tissue, but the producer said the viewers 
wouldn’t understand that. Stephen had a personal 
assessment of his body fat and at 40 per cent of 
body mass or 50 litres of real volume (it should be 
15 per cent) he was clearly concerned for his long-
term health as were one hundred thousand obese 
viewers. It was sensationalist TV at its best and was 
widely discussed even among those who live on 
takeaways six days a week.
XXL graves 
For me, it was not the excess day-glow-yellow 
human tissue or Stephen’s worried demure when 
he emerged from the body scanner, but, his 
concluding comment delivered in an American 
graveyard, where it is now common for people 
to be buried in double-width graves they are so 
obese, that hit me. It went something like this; 
“Junk food is sending me to an early death. 
Everybody has the solution. Eat less, exercise more. 
I don’t know, indeed no one knows, why people like 
me just can’t do it and that’s what’s killing me”. Cue 
sad reflective look into the middle distance, hold 
and cut! 
“I don’t agree,” I shouted at the director when 
I got my DVD copy. “We know exactly why 
Stephen is nearly seven stone overweight and 
that’s where we can do something”. “Put it in 
writing Mr Consultant,” she replied and asked 
that I keep my comments for the big debate 
to be broadcast live the evening following the 
programme. I, as a consultant, would be on the 
panel, live.
So I swotted up on the questions I was sent 
and I ran through in my head what killer points I 
would make. This is how it ran:
ObesOgenic envirOnment
Stephen; “So Terry tell me how bad obesity is in nI?"
Me, looking concerned and serious: “Well 
Stephen going back to 1980 only 6 per cent of 
the population were obese – now it’s about 25 
per cent. This is worse in lower social groups, 
among manual workers. It causes 25 per cent of 
CHD deaths, is the main reason for the 60,000 
type 2 diabetics we have and this is going up to 
80,000 diabetics by 2015 if we don’t change. We 
are talking a reversal in the major health gains we 
have made over the last 20 years. And the costs 
are painful too. Obesity costs the UK £3.7 billion. 
This will be £10 billion in 2050.”
Stephen looking shocked yet impressed: “And 
Terry tell us who’s to blame?”
Me, looking even smugger, with head nodding 
and lip biting Bill Clinton style: 
“I have a theory Stephen; the individual has 25 
per cent control over their weight; a further 25 
per cent the individual has a little, if any, control 
over. This is their desire, craving, eating compul-
sion, which controls them, and for many this can 
be impossible to override. It’s about the individ-
ual’s reactions to food. If you deal with stress, an-
ger, depression or boredom by emptying out the 
fridge or demolishing a family sized pack of crisps 
then you need behaviour modification help. The 
remaining 50 per cent is the obesogenic environ-
ment and the individual has no control: lack of 
opportunity to exercise in the built environment, 
no regulation of calorie-dense foods (sugars 
and fats) which are cheap and widely available; 
inappropriate advertising of dangerous foods, 
supermarkets who refuse to implement proper 
labelling and, finally, fast-food outlets of which 
there are too many serving the wrong types of 
food. Stephen, If we keep doing what we are do-
ing we keep getting what we’ve got”.
There would then be questions from an ap-
preciative audience and having given my insights 
and my answers my place in public health history 
would be assured. 
In the end it turned out somewhat differently. 
Two days before the “big debate” I got e-mail 
indicating, subtly, that I was being dropped from 
the panel. I arrived on time and was seated beside 
a charming woman who has lost a whopping 
seven stone.
The panel itself consisted of an overweight 
journalist, a painfully beautiful, lithe blonde who 
claimed to have lost seven stone on her own, 
a 30-something male who had also lost seven 
stone by gastric banding paid for by the health 
service, a highly irritating psychologist with an 
American accent and a specialist in childhood 
obesity.
The American accused, rather irresponsibly 
in my opinion, Stephen, our host, of being 
weak-willed in failing to control his weight. She 
persisted with this theme for much too long 
before accusing the gastric bypass patient of 
wasting £10,000 of health service money 
– the cost for his operation. What she 
knows about psychology was certainly 
greater than her knowledge of the 
cost of treating or even not treat-
ing diabetes and hypertension, of 
which this gastric bypass male, 
was now cured.
Bringing the audience into 
the discussions those keen to 
comment merely mentioned 
how much they had lost 
by attending a for-profit 
weight management 
programme.Challenged 
by one insightful mem-
ber in the audience that 
advertising of fast food 
to children was a key 
problem in obesity the 
comment was immedi-
ately deflected by the 
specialist in childhood 
obesity into concerns 
on the lack of specific 
help for obese children. 
later I was to find out 
he has an interest in an 
international hamburger 
company.
I did get to speak, briefly 
at the very end. I expressed 
concern that the real villains 
of the piece; processed food 
manufactures, fast food com-
panies and supermarkets were 
being let off the hook, but, I was 
cut off before I got finished. And 
so it was, my deep insights ignored 
and, I realised, as I walked alone to 
my car that with this level of public 
engagement hopes for a resolution 
to our obesity epidemic does not 
auger well. Too many vested interests 
hogging too much of the obesity 
problem by offering their solution only 
while the problem gets worse. And 
they haven’t even the decency to buy 
my book. And yes the painful part; I was 
one of them. 
My part in the ever-growing 
obesity epidemic 
Having been asked to share his views on the obesity 
epidemic on live television, Terry Maguire comes 
to realise that neither his opinion, nor those of his 
peers, alone can help to solve the growing problem. 
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creATive wriTinG
I 
read the following, or something like it 
recently, ‘a friend is someone who knows 
your song and sings it to you when you have 
forgotten it. Those who love you are not 
fooled by mistakes you have made or about 
the dark images others may say of you. They 
remember your beauty when you feel ugly; your 
wholeness when you are broken; your innocence 
when you feel guilty; and your purpose when you 
feel confused.’
Everyone’s got a song as a friend, even or 
more especially when they’re low. you’ll sing love 
songs, hum chords and broken tunes and maybe, 
even when broken, you’ll lift a bottle to a familiar 
tune and try and find the dream.
A song’s like a forecast; always got the 
potential of something about to happen. At any 
time it can surge or ebb, be it in the morning 
or maybe just to soothe to sleep. you’ve got 
melodies, where notes morph, melt, glide and 
collide from and into teasing lips. The note will 
show itself off like a girl in spring and then hide 
and fold into itself until the summer comes inside 
the song. 
notes can gather speed, stretch from Ross’ 
point as far as Rockhall, stand and soprano to 
Mizen or baritone their way down to Malin. And 
they’ll run away from you forever, over rainbows, 
along side factory walls, through the rain, trains 
with no sunshine, into deep velvet nights where 
you want to sink softly forever.
I’ll betray a few years and tell you I started 
pharmacy in Trinity in 1985. There’s not much of 
that Dublin left anymore, but recently I found 
myself in a place that brought me back to 
bedsit land. A friend got me a series of singing 
lessons in Walton’s School of Music in George’s 
Street. I have to admit I was pretty reluctant to 
go, even the welcome and assurance from Jo, 
the ever pillar of sense, when I got there didn’t 
help. I didn’t hear the cats, like me, only the 
mockingbirds and wanted to run, but the place 
had something going for it, like an orphan’s aura.
It’s a rabbit warren of old stairs and rooms 
with high bedsit ceilings and maybe it was the 
forgotten memory but that, for me, was the first 
anchor, it was like even the building itself could 
breathe. I’ve had the same teacher for three years 
now, a Polish lady called Marta. Communication 
can be fun there, but you don’t need words when 
you’ve caught a song, you don’t need words for 
that. 
Marta’s all about support, connecting the 
body, supporting the note. She’s tiny but she 
knows about support; when she sings it’s like all 
of Warsaw is behind her. Of late it occurred to 
me that’s what perhaps the school and it’s old 
biscuit redbrick are all about. That old Georgian 
house can empty itself of air, breathe and then 
it’s burren of high ceiling rooms support volumes 
of happiness. 
John Mardirosian and his better half set up the 
present school in 1994. Today, they have some 60 
teachers and approx 1400 pupils per term.
His mission is and I quote, ‘It’s about balance 
and choice. Music is a mysterious area for a 
lot of people and it can be intimidating. What 
is important is to demystify it up to everyone 
… and you have to have breath, you can’t be 
narrow.’ 
Or for children he has;‘Music is an outlet for 
children that’s every bit as valuable as sport and 
it’s also one that offers kids a clear indication of 
progress. If you practise a piece with any kind of 
application, then the next day you’ll be better at 
it.’
So, I recommend, in these somewhat dark 
times, to go over the rainbow, or go back to a 
memory and learn to sing. It’s as simple as that.
Oh, and there’s one other thing; on the way 
home, if she’s raining, you’ll feel the rain on the 
side of your cheek as opposed to getting wet. 
That’s what singing does. 
“That was the only time I ever heard Atticus say it 
was a sin to do something, and I asked Miss Maudi 
about it.
‘Your father’s right,’ she said. ‘Mockingbirds 
don’t do one thing, but make music for us to 
enjoy. They don’t eat up people’s gardens, don’t 
nest in corncribs, they don’t do one thing but sing 
their hearts out for us. That’s why it’s a sin to kill a 
mockingbird.’
jUl IAN jUdGE
Julian Judge qualified as a pharmacist in 
1990. he has recently completed a Masters 
in Creative Writing at the department of 
English at uCd. Contact Julian at email: 
julianjudge@hotmail.com
Mockingbirds in Waltons 
“When he gave us our air-
rifles Atticus wouldn’t teach 
us how to shoot. Uncle 
Jack instructed us in the 
instruments thereof; he said 
Atticus wasn’t interested in 
guns. Atticus said to Jim one 
day, ‘I’d rather you shot at 
tins in the back yard, but I 
know you’ll go after birds. 
Shoot all the bluejays you 
want, if you can hit ‘em, but 
remember it’s a sin to kill a 
mockingbird.’
The note will 
show itself off 
like a girl in spring and 
then hide and fold into 
itself until the summer 
comes inside the song.”
“
Northern Mockingbird
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IA IN CAhIll
Iain Cahill ACCA MBA QFA
director
Art of Wealth ltd.
dunlair house
old Athlumney
Navan
Co. Meath
Mob:  087 2411371
tel:  046 9072824
What to do 
with cash?
Aware that more and more people are increasingly 
worried about where to invest their hard earned cash, 
Iain Cahill shares his advice on how to invest wisely 
and safely. 
I
f like most people, right now, you are nervous 
about investing money in the current climate, 
then the challenge is what to do with any cash 
you may have in these very uncertain times. 
With the current upheaval in the Irish economy 
coupled with the continued threat of burning 
bondholders, IMF bailouts, the need to re-capitalise 
the banks and the continued government need to 
guarantee the banks, there is a lot of uncertainty out 
there. 
A key challenge is that of the continued uncertainty 
of the risks attaching to the various banks. With the 
latest round of bailout announced at €37 billion, it 
is still uncertain if this is enough to stabilise the Irish 
banking system. 
If we were to believe the financial journalists, the 
threat of a potential Eurozone break-up, would result 
in the dissolution of the Euro altogether or, more 
likely, the potential for a perceived two-tier value. In 
other words, that a German Euro is a far more precious 
currency than an Irish Euro. Before 2008, this would 
all have been conceived as a very unlikely occurrence. 
With the rising of the interest rate by the ECB and the 
need to bailout other European nations, unfortunately 
we must consider all possibilities in making informed 
choices. 
As already mentioned, the Irish government has 
continued to guarantee all deposits held within Irish 
institutions and after this is lifted (which has been 
threatened twice), the amount that is guaranteed will 
revert to €100,000 held within an Irish bank. note 
that for non-Irish banks, they are supported by the 
compensation rules applicable in the country of their 
parent bank. For example, deposits in Ulster Bank, as 
a subsidiary of Royal Bank of Scotland, are subject to 
the UK deposit combination policy. So why does this 
matter? 
safeguarding yOur mOney –  
the aLternatives 
In 1941, Will Rogers, a famous actor, once stated that 
'I am less concerned with the return on my money as 
the return of my money.' In the current climate, this is 
a good maxim to consider more most of us. 
In the search for potential solutions for clients, 
in conjunction with several institutions, we look at 
how best clients can access alternative strategies to 
simply chasing deposit rates. Through knowledge and 
planning, a number of potential solutions do exist and 
the rest of this article is about informing you of some 
of the alternatives that exist for cash investors. Some 
of you may be familiar with the alternatives that exist 
to cash deposits, but maybe you haven’t considered 
them in the context of a cash strategy. When I am 
working with clients, a true cash based investment 
strategy has as key components:
• The ability of the funds to be accessible 
when you need them
• Transparency in terms of charges 
and management fees
• Be transferable to other 
investment forms when required. 
I mention these key aspects as you would be 
amazed at what exists in the market, that under 
scrutiny does not make sense. In one particular case I 
reviewed on behalf of a client, the individual had been 
sold a two-year fixed rate policy by his bank with a 
perceived three per cent interest rate. However when 
you looked at the small print, he was being charged 
a 1.25 per cent management fee to manage cash. It is 
very hard to make a return on this sort of basis. 
a wOrd Of cautiOn 
It is always important to understand how returns on 
different strategies are taxed. It can make a difference 
and particularly in the current regime where taxation 
will become more penal as we move forward.
Secondly, it is worth your while being aware that in 
investment circles, many people talk about cash and 
cash equivalent investments. In this scenario we are 
therefore considering:
Investment type potential return
• Cash deposits. 0.1%-3%
• Money market funds. 1.2%-2%
• Sovereign bonds 2%-9%
• Corporate bonds 3%-15%
As you can see, there is some diversity in the 
potential returns that can be achieved under each 
of the investment headings. It is always worth 
remembering that the higher the return, the greater 
the risk or the accessibility to your funds. A classic 
example is what you see playing out with Irish banks. 
your current account might (if you are lucky) get an 
interest rate of 0.1 per cent on your money whereas 
you can get 6 per cent over two years (or three per 
cent pa) providing you lock your money away for two 
years. As we now know, two years is a long time in the 
current economic climate. 
reducing the risk 
There is a way that if you can combine these 
investments, it is possible to reduce the 
risk on being dependent on the Irish 
government to secure your 
deposits and make returns 
that are as good or better 
than you may be used 
to with your deposit 
returns.
What is vitally different 
about this potential matrix approach is that your 
funds also remain accessible whenever you wish to 
access them.
If you followed the results of the first of the 
repossession auctions last month, it may appear that 
there is a market for Irish property with strong rental 
yields (assuming the tenant remains in situ) and 
maybe we all will find some interest in property again. 
Having access to liquid funds means that you will be 
in a position to take advantage of opportunities as 
they present themselves. Although if you can get 6.5 
per cent return on your money and greater certainty 
on the risks, it does make a compelling argument for 
whether you need alternative investments at all?
There is no doubt that if people had been aware of 
alternative ways of making income on their money, 
they would have been less inclined to invest in 
dividend stocks, which the banks offered and instead 
had a similar return within the fear of loss. While a 
painful lesson has been learned for many people, we 
can at least prevent this from happening again. 
As I introduce more knowledge of what to do in 
the current environment, please do not hesitate to 
give me a call or send me an email if you have any 
queries. Until then, happy and safe investing.
In 1941, Will Rogers, 
a famous actor, 
once stated that 'I am 
less concerned with the 
return on my money as 
the return of my money'. 
In the current climate, 
this is a good maxim to 
consider. “
“
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n these dark days of austerity 
and the seemingly unending 
media reports of negative 
equity, successive cuts to our 
credit rating and IMF doom and 
gloom, it is worth remembering 
that despite the recession, Ireland’s 
long held reputation for excellence 
in science, technology and research 
is still going strong. 
nowhere is this more evident 
than in the numerous developments 
in science and biotechnology 
that continue to emerge from our 
universities. 
The development of an innovative 
class of platinum drugs and an 
advanced new system for the 
treatment of lung cancer; these are 
just some of the good news stories 
to emerge from Irish universities in 
recent weeks.
a marriage of commerce and 
academia 
In fact, addressing the Digital 
Enterprise Research Institute (DERI) 
open day which took place at nUI 
Galway recently, the newly elected 
Minister for Research and Innovation, 
Seán Sherlock TD said that research 
between commercial and academia 
sectors represented “a winning 
formula for our economic recovery.”
DERI, a Centre for Science, 
Engineering and Technology (CSET), 
which is supported  the Government 
through Science-Foundation Ireland 
(SFI) funding, was established in 
2003, as a web science research 
centre. Current research projects 
include semantic search engines, 
novel collaboration and social 
media as well as sensor network 
technologies.
According to Minister Sherlock, 
“the clustering model of 
scientific research, comprising 
an unprecedented degree of 
co-operation and collaboration 
between commercial and academic 
personnel, has been “a winning 
formula” at DERI.
The DERI Open Day was 
attended by over 250 academics 
and industrialists who attended 
presentations and demonstrations 
on DERI’s research, applied research 
and commercialisation activities. 
According to Minister Sherlock 
DERI’s impressive track record also 
provided the Government with 
“considerable hope and indeed 
some expectation that science 
will be pivotal to our economic 
recovery.”
Coupled with the excellent work 
being carried out by researchers at 
DERI and indeed throughout nUI 
Galway, a number of other Irish 
universities have recently published 
details of exciting new research 
projects, all of which underline 
the key role science, technology 
and research can play in assuring 
Ireland’s economic future. 
Platinum drugs 
At the RCSI, for example, Dr Celine 
Marmion (Principal Investigator) 
and Dr Darren Griffith from the 
Department of Pharmaceutical 
and Medicinal Chemistry have 
recently discovered an innovative 
class of platinum drug candidates 
for the treatment of cancer, which 
has recently been licensed to a 
pharmaceutical company for further 
development. 
The novel technology, developed 
at RCSI, has focused on the 
development of multi-functional 
platinum drug candidates, 
which within cancer cells would 
simultaneously target DnA and 
a class of enzymes called histone 
deacetylases (HDAC). These 
platinum drug candidates have 
demonstrated potent anti-cancer 
activity and have been shown to be 
selective for cancer cells over normal 
healthy cells. 
Commenting on the RCSI project 
Dr Celine Marmion said, “success 
in drug development depends on 
a multi-disciplinary approach. In 
addition to having an excellent 
research group, we have been 
very fortunate to have strong 
collaborative links internally (Dr M 
Morgan, MCT, RCSI), nationally (Dr D 
Egan, IT Tallaght and Dr K Kavanagh, 
nUI Maynooth) and internationally 
(Professor V Brabec, Academy of 
Sciences of the Czech Republic)." 
new cancer treatments
There was more good news on 
the development of potential new 
treatments for cancer from UCC 
last month with the news that 
an advanced new system for the 
treatment of lung cancer was one of 
two new technologies to be named 
UCC Invention of the year. 
The Invention of the year Award 
recognises the world-class research 
being undertaken at UCC, which has 
developed a strong track record in 
commercialising and spinning-out 
projects in disciplines ranging from 
life sciences and pharmacology to 
ICT and engineering. 
The invention by Declan Soden 
and John Hinchion, principal inves-
tigators at the Cork Cancer Research 
Centre, is a new laparoscopic device 
for the non-invasive treatment of 
lung cancer.
The lung laparoscopic Electropo-
ration Electrode (llEE) delivers, in a 
targeted manner, an electrical field 
to tumour tissue and as a result an 
electrical field is generated around 
the tumour, which opens microscop-
ic pores within the cancerous cells, a 
process known as electroporation. 
With these microscopic pores 
opened, a cytotoxic cell-killing 
drug is delivered directly into the 
cancerous cells. The drug absorption 
occurs only in the area that has been 
electroporated (i.e., when the cell 
pores are opened using electrodes) 
and the treatment is directly 
targeted into the cancerous cells 
in the tumour, leaving surrounding 
healthy tissues unaffected. 
The UCC medical device will now 
undergo clinical trials to prove its 
effectiveness. 
Electrochemotherapy is already an 
acknowledged treatment method in 
skin cancer and Declan Soden is also 
an inventor of the EndoVE, a device 
currently in clinical trial to treat 
colorectal cancer, but a similar lung 
treatment has not been developed 
until now. The system underlying 
the new device is currently being 
patented by UCC’s Technology 
Transfer Office.
According to UCC President, Dr 
Michael Murphy, “The ability to 
commercialise Irish research projects 
and to bring them to a global 
market will be a vital contributor 
to the renewal and recovery of our 
economy. Innovative research at 
UCC is yielding a tangible return 
on investment for the State and 
benefits for industry, society and the 
economy through the licensing and 
spinout of patented research and 
new companies."
Other inventions shortlisted in 
the UCC competition included a 
new system to maximise broadband 
data transmission in fibre optic 
cables; a controlled drug delivery 
system for illnesses including 
Crohn’s disease and stomach cancer; 
intelligent software systems for 
the evaluation of customer service 
quality in contact centres; the use of 
nanotechnology in the development 
of new drugs and a software 
technology that helps retailers to 
evaluate and extend the shelf life of 
fruit and vegetables.
Several other UCC research 
projects and inventions were also 
very highly commended in the 
evaluation process.
From bench to bedside 
At a time when tough decisions and heartbreaking tales are dominating the 
news agenda, June Shannon takes a look at the good news. 
pictured iis declan Soden, principal Investigating officer, uCC, Cork 
Cancer research Centre with uCC president dr. Michael Murphy. 
Michael Mac Sweeney/Provision 
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t
he objective of this article is to 
inform the reader of the natural 
progression of allergy from 
childhood to adulthood so that 
the ‘Allergy March’ can be halted 
at an early stage in life. Allergy is 
a combination of genetic and environmental 
factors, and therefore because we are unable to 
control the former, it is important to ascertain 
what the triggers of allergy are so we can limit 
this exposure. In Ireland, we must be extra 
cautious when discussing allergy diagnosis with 
patients as many of them seek the assistance 
and diagnosis of alternative practitioners with 
dubious ways of testing for allergy. The patient is 
not entirely at fault as the waiting lists to be seen 
by public immunology services range between 
many months up to two years sometimes. It is 
essential therefore that scientific and validated 
methods be used for allergy diagnosis.
aLLergies effecting babies
There appears to be a set pathway, which 
allergies seem to take from childhood to 
adulthood. A baby who has allergies usually 
presents with food allergies and typically may 
present with abdominal colic, although this 
symptom has many aetiologies. The colic may 
coexist with eczema and this eczema usually 
affects the flexural surfaces of the arms and legs 
in younger children. These early allergies may be 
caused by the proteins found in cow’s milk and  
breast-feeding is advocated in all cases and the 
recommended duration remains at a minimum of 
six months.
One important fact to note is that parents and 
medical practitioners should not switch to soya 
protein formula without due investigation as 
almost half of cow’s milk protein allergic children 
will also be allergic to soya formula – this is why 
some children’s allergy worsens after changing to 
soya formula. Allergy testing will have diagnosed 
this at an early stage. All that is required is an 
allergy skin prick test or a specific IgE blood test.
Cow’s milk protein allergy (CMPA) babies now 
have the option of hypoallergenic formulas 
where the cows milk protein has been partially 
or extensively hydrolysed, in order to reduce 
dR RANbIR KAUlsAy Md. FACAAI
MEdICAl AllERGIsT 
ClONTARF Cl INIC AllERGy CENTRE 
& bERKElEy ROAd AllERGy ClINIC, 
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the progression of 
allergies 
In some children 
allergy may not 
be noticed until they 
reach the weaning 
period when foods 
are introduced for the 
first time. Eight foods 
account for 90 per 
cent of all food allergic 
reactions. 
“
Aalmost one in three patients suffer from some type of allergy, it  is therefore 
of great importance that pharmacists familiarise themselves with all aspects of 
allergy.
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the allergenic potential of the formula. The 
nutritional component remains the same; it tastes 
slightly more bitter and these formulas are easily 
available either as partially hydrolysed formula 
for moderately allergic children or extensively 
hydrolysed or amino-acid formulations for 
more severe cow’s milk protein allergic children. 
These formulas are more expensive than normal 
formulas and some may be on the medical card 
or drug payment scheme (DPS).
In the past it was believed that cow’s milk 
allergy disappeared in approximately 85 per 
cent  of the sufferers by the age of three years, 
but recent studies have demonstrated a more 
delayed time to lose this allergy. Other foods like 
shellfish and nuts remain a life long burden.
tOddLer aLLergies
In some children allergy may not be noticed until 
they reach the weaning period when foods are 
introduced for the first time. Eight foods account 
for 90 per cent of all food allergic reactions. They 
are milk, egg, peanut, tree nuts, fish, shellfish, 
soy , wheat and  egg protein where egg white 
is the predominant allergy. This allergy is rather 
difficult to avoid because egg white or albumin is 
found in a great range of foods and label reading 
becomes important for the parent. I have heard 
from dietitians that deal with allergy that the 
duration of the average supermarket shopping 
trip is doubled when shopping for a child with 
food allergy due to the necessary label reading 
that has to occur.
Wheat allergy is another common allergy and 
this can be a major inconvenience because of the 
variety of commonly consumed foods that are 
made from or may contain wheat. The presenting 
complaints of this allergy can be anything 
from skin rashes or eczema to gastrointestinal 
complaints. Thankfully in modern day Ireland, 
there are many wheat or gluten free substitutes 
available. It is at this stage that I would like to 
introduce the concept of intolerances and how 
this differs from a true food allergy is that it is not 
mediated by the same immune mechanisms as 
allergy – very frequently the reactions take longer 
to occur and the clinical picture often presents as 
bloating and gastrointestinal problems and there 
are many unknown factors where intolerances 
are concerned. The tests for intolerances are 
many and varied and only a few have scientific 
merit, but a lot of research continues to occur in 
this field.
OLder chiLdren and aduLts
It is here that the spectrum begins to change and 
inhalant allergies begin to become important. 
Usually towards the end of the first decade of 
a child’s life and this age seems to be getting 
younger and younger the child may become 
allergic to environmental allergens. The most 
common environmental allergens are house dust 
mites, pollens, mould spores and pet dander. 
These allergens are commonly responsible for 
causing seasonal or  intermittent allergic rhinitis 
(hay fever) or more persistent house dust mite 
induced persistent allergic rhinitis. Any one of 
these allergens can cause allergic asthma and 
may cause eye, nose and lung symptoms. 
Thankfully, these allergies are easily identifiable 
by skin prick testing or specific IgE measurements 
and the practitioner is then able to offer 
avoidance advice, or better still ,refer the patient 
to a medical allergist or clinical immunologist so 
as desensitisation may be prescribed. 
The main desensitisation or immunotherapy 
offered recently is via the sublingual route 
as this is the safest, easiest and most cost 
effective method. In the instance of grass pollen 
desensitisation, this treatment can be prescribed 
by selected specialist throughout Ireland to 
be continued by their GPs and this three year 
protocol of sublingual tablets will then confer 
desensitisation to grass pollen for the next 
decade at least. This treatment is available on 
the GMS and Drug Payment Scheme. This is the 
main treatment being advocated by the WHO 
as this is the only therapy that alters the natural 
course of the disease and may prevent the 
occurrence of new sensitisations. Personally, I 
have had very good experiences with sublingual 
desensitisation for pollens, dust mites and even 
pet dander over the last 10 years. There are very 
few side effects and there has yet to be a case 
of anaphylaxis with these treatments in clinical 
practice. Unfortunately, we are not able to offer 
such therapies for food allergens and a lot of 
research is on going in this field currently but no 
commercial preparations are available as yet.
the end Of the ‘aLLergy march’
There are many things that we can do to decrease 
or even halt the ‘allergy march’.
Although genetically, there is nothing that 
may be done to improve this situation apart from 
careful selection of one’s partner, preferably with 
no family history of allergy, during pregnancy, 
especially in the third trimester for mothers with 
a strong family history of allergy, research has 
advocated an increased intake of omega-3 fish 
oils and house dust mite avoidance. These two 
steps are the only scientifically proven methods 
of reducing the incidence of allergy in a ‘high risk 
of allergy’ baby.
Once baby is born, to a family with a history of 
asthma, eczema, allergic rhinitis or other allergies, 
they have to be extra vigilant for the occurrence 
of eczema and should be aware of the different 
foods that may cause an allergy when weaning. 
Breast-feeding as always is recommended at least 
for six months and some research advocates the 
use of hypoallergenic formulae thereafter, but 
personally this should be on a case-to-case basis. 
If symptoms occur, early testing and therefore 
avoidance will be logical so that the natural 
progression of allergy may be halted. 
The reduction of house dust mite exposure 
should be advocated for anyone with a family 
history of asthma, rhinitis or eczema because it is 
with a very high probability that the child may be 
dust mite sensitive due to the high incidence of 
this allergy. 
Furthermore, it is relatively straight – forward 
to do so – no carpets in the bedroom or at least 
regular vacuuming with a high quality vacuum 
cleaner, dust mite barrier covers for the mattress, 
pillows and duvet, 60-90°C weekly sheet washes, 
de-cluttering of the room and washing of soft 
toys etc.
Should an allergy be detected, early avoidance 
is paramount and the earlier desensitisation is 
commenced the better especially when exposure 
cannot be avoided eg. pollen allergy. If the first 
line of medical care were on the lookout for 
these early symptoms, many of these babies and 
potentially allergic patients may be detected at a 
much earlier stage. 
Once baby is born, 
to a family with 
a history of asthma, 
eczema, allergic rhinitis 
or other allergies, they 
have to be extra vigilant 
for the occurrence of 
eczema and should be 
aware of the different 
foods that may cause an 
allergy when weaning. 
“
the progression of Allergy from Childhood to Adulthood 
Allergy March Illustration with permission from Dr Ranbir Kaulsay – theallergymarch.com / www.clontarfclinic.com
Because congestion can impact your 
patients with allergic rhinitis any time of year... 
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Irish city 
dwellers 
have higher 
skin cancer 
risk, study 
shows 
Irish Times, 2 September 2010
In addition to 
advising patients 
about how to protect 
themselves against the 
harmful rays of the sun, 
pharmacists are often 
also the first port of call 
for patients who have 
any concerns about 
changes to their skin 
and as such, can have 
an important role to 
play in advising their 
patients about the signs 
and symptoms of skin 
cancer.”
d
espite the fact that skin cancer is 
the most common form of cancer 
in Ireland, the reality is that it is a 
subject that many people remain 
ill informed about. 
In fact, it’s likely that if you 
were to ask your average patient to name the 
different types of skin cancers and how they can 
protect themselves from these, some might have 
difficulty in differentiating between malignant 
and non melanoma cancers, the different ways 
they can protect themselves from these or 
perhaps, most importantly the fact that a very 
significant number of cancers caused by the suns 
rays are preventable. 
Taking this gap in knowledge into 
consideration, Melanoma Awareness Month 
(which takes place this May), presents itself as a 
perfect opportunity for pharmacists and other 
health professionals to educate themselves about 
the incidence of skin cancer in Ireland and look at 
the ways they can help their patients to be more 
skin aware. 
skin cancer – the facts
• Skin cancer is the most common cancer in 
Ireland 
• Over 8,000 new cases of skin cancer were 
diagnosed in 2008
• Of these 721 cases related to malignant 
cancers; 308 cases involved men and 413 
involved women. The rest of these cases relate 
to non-melanoma cases
what is skin cancer?
There are two main types of skin cancer namely 
non-melanoma and malignant melanoma. 
non-melanoma skin cancer is most commonly 
diagnosed in people who spend a lot of time 
outdoors. There are two forms of non-melanoma 
skin cancer namely basal cell carcinoma and 
squamous cell carcinoma. 
Basal cell carcinoma is most common in fair 
skinned and older people and is caused by over 
exposure to the sun. 
Squamous cell carcinoma is a slow growing 
skin cancer also caused by over exposure to the 
sun. It usually affects older people and occurs on 
areas exposed to the sun such as your face, ears, 
neck or lim
Basal cell carcinoma and squamous cell 
carcinoma are often recognisable by the 
development of a new sore or growth that does 
not heal within four weeks, a spot or sore that 
continues to itch, hurt, crust, scab or bleed; or 
constant skin ulcers that are not explained by any 
other cause.
Malignant melanoma is the most serious form 
of skin cancer. It occurs in the melanocytes of the 
epidermis, which are the cells that give the skin 
colour. It is often identified by the development 
of a new or changing mole or freckle.
skin cancer and the rOLe Of the 
Pharmacist 
PreventiOn 
Jennifer ledwith, Cancer Information Services 
nurse with the Irish Cancer Society says that 
pharmacists can play a major role in helping to 
reduce their patients risk of skin cancer and to 
build awareness around the disease. 
“nine out of ten skin cancers are caused by 
the suns rays and these can be prevented. It’s so 
important that we look at how much time we 
are spending in the sun – especially with regard 
to children and young people as the damage 
done to young people by the sun shows twenty 
years on. The simple message, which needs to be 
reiterated over and over again, is to use the sun 
smart code and protect yourself, “ she said. 
This code, recommends that people protect 
themselves from the sun by covering up, seeking 
shade during the hottest parts of the day, protect 
their  eyes, use sunscreen and steering clear of 
sunbeds and sunlamps. 
“
The burning issue 
As Melanoma Awareness Month 
draws upon us, Mary O’Keeffe 
takes a look at the incidence of skin 
cancer in Ireland and asks what role 
pharmacists can play in the battle 
against the disease.
MARy O’KEEFFE
92 per cent increase in 
cases of skin cancer 
www.rtE.ie, Monday, 10 May 2010
Dramatic rise 
in malignant 
skin cancer in 
young people 
www.bbc.co.uk, 25 August 2010
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“We always tell patients that it is just so 
important to protect yourself by wearing the 
appropriate clothing such as a wide brimmed 
hat and long t-shirt, by using umbrellas, wearing 
sunscreen and remembering the slogan ‘from 
one to three, sit under a tree’
“What Irish people tend to forget is that the sun 
is just as dangerous here as it is in other places. In 
fact, it can sometimes be even more dangerous, 
as because we only get it occasionally, we have a 
tendency to stay out in the sun for too long and 
this is very hard on the skin,” she said. 
Use sunscreen and protect the eyes
Ms ledwith said that pharmacists have an 
important role to play in helping ensure their 
patients are using the correct sunscreens for their 
skin. 
“If people are in and are looking around and 
thinking of buying the sun creams, pharmacists 
can use this as an opportunity to raise awareness 
of the importance of sun screen and of the Sun 
Smart code. 
“For a start, they can help patients to 
understand the labeling of the screen. All 
sunscreen should have an ‘A’ logo on it. 
Furthermore, pharmacists can advise patients 
about what factor they really need – as a general 
rule of thumb we say factor 15 or higher is 
perfect for the average person. When it comes 
to applying sunscreen, pharmacists should tell 
people to apply sunscreen every two hours using 
a teaspoon of sunscreen for each limb and a golf 
ball of sunscreen for the body. It’s important that 
parents take extra care ensuring their children 
are well covered up. Children can do a patch test 
of the sunscreen to make sure that they are not 
allergic to it before use. We would also advise 
that all babies under six months of age are not 
out in the sun at all,” she said. 
Ms ledwith also recommended that if patients 
have questions about how to protect their eyes 
that their pharmacist reminds them that to 
protect their eyes from the sun they need to wear 
sunglasses which either have the En standard 
1836 or the BS standard BS27241587. 
Know your skin type and your risk 
norma Cronin, Health Promotion Manager with 
the Irish Cancer Society says that pharmacists can 
also help their patients reduce their risk of skin 
cancer by helping them to understand their own 
skin type and their risk of the disease. 
“It is so important to remember that anyone 
who spends a lot of time outdoors and not just 
those who sunbathe or go on sun holidays, are 
at risk of skin cancer such as people who work 
outdoors or play a lot of outdoor sports like golf. 
People should also take extra care if they are 
pale, fair or have freckled skin, if they burn easily 
or burn before they tan, if they have red or fair 
hair, green or blue eyes or have a large number of 
moles (more than 50),” she explained. 
Ms Cronin added that it is also important that 
pharmacists advise people that those who use 
sunbeds are also at an increased risk of skin 
cancer. “The use of sunbeds continues to pose a 
problem here in Ireland and we are continuing our 
campaign for increased legislation surrounding 
the use of sunbeds both for under 18s and people 
in general. Sunbeds have now been classified by 
the world health organization as carcinogenic, but 
there is a lack of information out there about just 
how dangerous they are” she said. 
signs and symPtOms Of skin 
cancer 
In addition to advising patients about how to 
protect themselves against the harmful rays 
of the sun, pharmacists are often also be the 
first port of call for patients who have concerns 
about changes to their skin and as such, have an 
important role to play in advising their patients 
about the signs and symptoms of skin cancer. 
“The signs which we would tell pharmacists 
to tell people to look out for are scaling on the 
skin which keeps coming back (this could be 
squamous cell carcinoma), a new growth or 
a mole that changes in size, that doesn’t heal 
in four weeks, constant skin ulcers not related 
to other issues and melanoma type changes 
such as moles that are bleeding or that change 
shape, size or colour. People should also look out 
for burns as these can easily become infected. 
If people have any concerns, it is important 
to recommend that they seek the advice of a 
doctor,” concluded Jennifer ledwith, Cancer 
Information Services nurse with the Irish Cancer 
Society. 
The Irish Cancer Society provides a number of 
tools aimed at helping pharmacists to ensure their 
patients are skin cancer aware including providing 
them with health promotional materials. 
The society also offers special training for 
pharmacists on the Sun Smart Code.
For further information on these courses please 
contact Dominique at the Irish Cancer Society on 01 
231 0541. 
the Sun Smart Code 
1. Seek shade 
• Staying in the shade is one of the most effective ways of reducing exposure to ultraviolet 
radiation.
• Any shade will do. It can be from a building or a portable umbrella.
• Plan your outdoor activities to avoid exposure to ultraviolet radiation when it is at its 
highest, between 11am and 3pm.
2. Cover up 
• Wear a wide-brimmed hat or a hat with a neck flap to cover the neck.
• Wear a t-shirt or other shirt with a close-weave material 
3. protect your Eyes
• Wear sunglasses that give a high protection against UV rays. look at the label and check the 
standard: BS Standard (BS 27 24 19 87) or European Standard (En 1836).
4. use sunscreen 
• Use a sunscreen with an SPF or 15 higher/ Medium or higher and UVA protection
• Put sunscreen on 20 minutes before you go out into the sun.
• Put on more sunscreen every two hours.
• Put it on more often if you have been swimming or sweating
5. Avoid sunbeds and sunlamps
• Sunbeds and sunlamps increase your risk of skin cancer. If you want to protect your skin, 
don’t use them.
Skin cancer Models ronan Carroll and donna lyons not acting SunSmart
As a part of May: Melanoma Awareness Month, developed in Ireland by La Roche-Posay in 2008 with the support of the Irish Cancer Society, La Roche-Posay 
launch SOS Save Our Skin.  This public awareness campaign works to address the increasing problem of skin cancer in Ireland.  This campaign is supported by the 
Department of Health and the Minister for Health, Dr James Reilly, will officially launch the campaign on April 28th 2011.
Did you know?*
 • The most common cancer in Ireland is skin cancer with over 8000 new cases diagnosed in 2009.
 • 90% of all skin cancers are preventable.  Virtually all the risk comes from the sun and sun beds**
 • We receive up to 80% of our sun damage before the age of 20, so protection in children is vital**
 • In Ireland, 1 in every 8 men and 1 in every 10 women will develop skin cancer by the age of 74 years**
 • 66% of Irish people have a higher risk of developing skin cancer because of their skin type **
 *NCRI  **www.cancer.ie/sunsmart
Melanoma Awareness Month is a global initiative to promote the early detection and prevention of skin cancer. In Ireland, La Roche-Posay is driving the month 
long awareness campaign for the fourth year running, alongside the Irish Cancer Society, Dr Patrick Ormond Consultant Dermatologist¹, as well as Melanoma 
Trust².  Also Eccles Private Clinic³ in association with the Mater Private Hospital³ is offering free Specialist Diagnostic & Surgical Support on May 25th³.
This year, the new look campaign is called SOS Save Our Skin, to highlight the severity and urgency of the cause. It is a nationwide effort being promoted in 
Dermatologists rooms, Dermatology departments, GP surgeries, pharmacies and social media encouraging members of the public to get their moles/suspicious 
legions checked and adopt safe behaviour in the sun.  
SOS Save Our Skin is a month long drive to raise awareness and to prevent the increasing problem of skin cancer in Ireland.  Research has indicated that Melanoma 
will continue to rapidly rise in Ireland, with an increase of 41% in incidences of skin cancer in the last 10 years from 5776 in 2000 to 8145 in 2009 and we could see 
a trebling of malignant melanoma rates over the next 30 years* with people being diagnosed at a progressively younger age.  These committed parties together 
with the backing of the Department of Health, could help to prevent these increased figures. 
1.  The Sharon Rice O’Beirne Melanoma Trust 
was set up in memory of Sharon, who on the 2nd of 
February 2008 lost her brave battle against Melanoma 
Skin Cancer. The aim of the Trust is to bring about an 
awareness of this potentially fatal disease and to help 
fund Irish research in this particular area. Sharon’s great 
strength and positive attitude throughout her illness 
has encouraged her family & friends to try and promote 
awareness of this devastating disease to more people who 
are potentially at risk.
2.   
Eccles Clinic FREE Specialist Surgical Support to the SOS 
Save Our Skin campaign 
Eccles Clinic, founded by consultant plastic surgeon, 
Denis Lawlor FRCSI, in association with the Mater Private 
Hospital offers FREE Surgical Support to the SOS Save Our 
Skin campaign. On Wednesday, May 25th 2011, patients 
without health insurance who have been assessed by 
their GP  and considered appropriate for referral to Eccles 
Clinic will be seen by Mr Lawlor for free treatment where 
necessary. For consideration, the referral must reach 
the clinic by letter, fax (01 8303296) or email (info@
ecclesclinic.ie) by the 16th May. Subject to appointment 
availability, this is for a limited number of patients on May 
25th.  If a growth is suspicious, it will be excised and the 
excised growth will be sent to the pathology department 
at the Mater Private Hospital, where it will be examined 
for free.  Mr Lawlor is on the Plastic, Reconstructive 
and Aesthetic surgery section of the medical council 
(registration number: 06002) and also a member of the 
Irish Association of Plastic Surgeons. 
Last year through this program, Eccles Clinic saw 64 
people of which 47 were women and 15 were men. 31 
required surgery, of which 25 were benign and 3 (9.6%) 
were a melanoma, 2 (6.5%) were squamous cell carcinoma 
and 1 (3%) was basal cell carcinoma.  Overall, of the 31 
cases, 19% were malignant. For further information on 
Eccles Clinic: www.ecclesclinic.ie.
3.  La Roche-Posay’s sun 
protection range, Anthelios, provides unparalleled 
effectiveness and dermatological tolerance to protect 
against cell damage caused by UV rays offering the most 
effective sun protection on the market.  Anthelios XL 
filtering system has the highest level of UVA protection 
available of the market. It has a UVA protection level of 
PPD42, 12 points higher than the previous formula. La 
Roche-Posay, the brand of choice of 25,000 dermatologists 
worldwide, has demonstrated its efficacy of Anthelios XL 
via 21 clinical studies (4 in vitro and 17 in vivo).  The in 
vivo clinical studies were carried out on patients suffering 
from sun intolerance reactions, particularly those caused 
by UVA rays. Anthelios filtering system ensures efficient 
protection against the entire spectrum of UVB-UVA rays; 
whatever their intensity.
La Roche-Posay further demonstrates its commitment to sun protection and sun education by donating €1 to the Irish Cancer Society for every purchase of Anthelios 
Fluid Extreme 50+ in 2011.
Every year, La Roche-Posay promotes SOS Save Our Skin – May Melanoma Awareness Month in Ireland. Together with the support of the Department of Health, the Irish Cancer 
Society, Dr Patrick Ormond Consultant Dermatologist¹, the Melanoma Trust², and Eccles Private Clinic³ in association with the Mater Private Hospital³ the campaign grows each 
year to raise awareness and to help prevent increasing cases of skin cancer in Ireland. Also this year, La Roche-Posay is the official sun protection sponsor of Race the Rás, a charity 
cycle in stages around Ireland involving GAA legends to raise funds and awareness for the Irish Cancer Society Skin Cancer Awareness Campaign and GOAL. 
MAY: Melanoma Awareness Month 2011 – SOS Save Our Skin
– La Roche-Posay, dedicated to driving back Skin Cancer in Ireland –
www.sossaveourskin.ie
- SAVE OUR SKIN -
www.sossaveourskin.ie is a public health website dedicated to the early screening of skin 
cancer. It enables each individual to learn more about skin cancer, safety in the sun and to diagnose 
their personal risk level, self-check moles and mole map. It is a tool to support dermatologists in 
their effort to educate the wider public. 
La Roche-Posay³ is urging the Irish public to look out for new lumps, growths or changes to 
existing moles, and also to be vigilant about monitoring moles in general.  All details and pictures 
for reference are available on www.sossaveourskin.ie and any observed changes of moles 
should be discussed with a dermatologist or General Practitioner without delay.
These may be the early signs of skin cancer and early detection is vital for successful treatment.
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What is epilepsy?
There’s no denying the fact that epilepsy is a 
complex and often misunderstood condition. In 
fact, with the wide range of forms of epilepsy, 
numerous treatment options and routines, 
not to mention the many drug interactions 
with epilepsy medications, it’s not surprising 
that there are still a vast number of myths 
surrounding what epilepsy actually is and how it 
should be treated. 
Brainwave, the Irish Epilepsy Association’s 
definition of epilepsy is:
“To have epilepsy is to have a tendency to have 
recurring seizures. Anyone can have a seizure, if 
the brain is exposed to a strong enough stimulus. 
We know that about 1 in every 20 people will 
have a single seizure at some time during their 
lives.”
Myths and misnomers 
According to Geraldine Dunne, Information 
Officer for Brainwave, awareness of epilepsy “is 
an issue across the developed world”, not least 
because of the fact that there are just so many 
myths surrounding the disease. 
Ms Dunne says that Brainwave is constantly 
working to dispel these myths and increase 
communication and knowledge around the 
condition to try and quash these mistruths 
amongst health professionals, patients and 
members of the public. 
“One of the myths about epilepsy which 
comes up again and again is that you should put 
something into someone’s mouth when they are 
having an epileptic fit to stop them from biting 
their tongue. This is not true. For a start, you can’t 
really prevent someone from biting their tongue 
and even if they do [bite it], while it might be 
disturbing to look at because there may be blood 
when they bite the surface tissue, the reality is 
that this tissue will heal. If you put a spoon into 
someone’s mouth, you may actually cause him 
or her more serious damage as this may break 
all his or her teeth. Recently, we heard of a case 
where one person swallowed part of a denture as 
a result of this,’ she said. 
Ms Dunne explained how Brainwave is also 
working to quash the myth that people with 
epilepsy cannot ever drive. She said that this is 
simply not the case, and that the ability to get a 
drivers licence in actuality depends on the type 
of epilepsy someone has or how long it is has 
been since there last seizure. 
“Another myth that comes up over and over 
is that everyone with epilepsy is affected by 
flashing lights. This is also not the case and many 
people with epilepsy are not photosensitive. We 
get a lot of people coming back to us because 
their consultant has not told them they are 
photosensitive and so they may have concerns 
about using a whiteboard or a computer, but 
often, it’s a case that there consultant has just not 
specified that they are not photosensitive,” she 
explained. 
Epilepsy and the role of pharmacist 
According to hospital pharmacist and board 
member of Brainwave, Margaret McCahill, there 
are a number of things which pharmacists can 
do to help their patients to better understand 
their condition and to ensure that they keep their 
patients safety at the top of their agenda. 
This, according to Ms McCahill, begins with 
providing simple, easy to understand advice 
about epilepsy and medications to patients who 
are newly diagnosed with the condition. “The 
drug treatment of epilepsy is very complex and 
while the lucky ones are maintained on one drug, 
some will need two or three and often there are a 
lot of interactions with some of these drugs. 
“When a newly diagnosed epilepsy patient 
comes to the pharmacist for the first time they 
are probably still going to be in a state of shock 
about their diagnoses. First and foremost, it’s 
important at this stage that the pharmacist keeps 
the consultation with his/her patient as simple as 
possible initially and reiterates that if and when 
the patient has any questions to come back with 
these. Some of the things the pharmacist can do at 
this stage is to explain the early side-effects of their 
new medications and advise them about the side 
effects which they need to look out for,” she said. 
According to Ms McCahill, some of the more 
common side effects of the medicines which 
people should be made aware of are the 
transitory symptoms such as stomach upset 
and drowsiness as well as visual disturbances. 
“It is important that patients are aware of these 
symptoms and the ones which they need to look 
out for as some of these can sometimes indicate 
toxicity for example, sometimes, as a result of a 
drug interaction,” she said. 
Ms McCahill also recommended that 
pharmacists advise their patients that it might be 
a good idea to have their bloods checked soon 
after starting these medicines to make sure these 
are working. 
other issues and contraindications 
Ms McCahill stressed that pharmacists should not 
only advise their patients about the possible drug 
interactions associated with epilepsy medicines, 
but should also make them aware of other issues 
and contraindications associated with epilepsy 
medicines. 
“Pharmacists need to explain to patients that 
there are a number of other factors which can 
affect/be affected by their epilepsy medication 
Firstly, in patients who might have another 
condition, it is important that they realise that 
some medicines may lower their drug threshold. 
It is also really important that you tell patients 
to always remind their doctor and their dentist 
that they are epileptic and that if they come to 
you saying that they have found out that they 
are pregnant that you tell them to see their 
neurologist or obstetrician. It is also important 
to tell patients that some of the anti-epileptics 
can cause osteoporosis and that they may need 
to take calcium whilst taking their medicines just 
as it is important to advise women that they may 
need to take a higher dose of the contraceptive 
pill than normal to prevent pregnancy whilst 
taking their epilepsy medicines,” she said. 
National Epilepsy Week takes place from May 16 
to 22, 2011
As part of the event, Brainwave will host a number 
of events, seminars and outreach clinics aimed at 
raising awareness of epilepsy, quashing the myths 
surrounding the condition and educating patients 
and health professionals about it. For further 
information on events taking place as part of the 
weeklong campaign contact Brainwave; the Irish 
Epilepsy Association on Phone: 01-4557500, e-mail 
info@epilepsy.ie or log on to www.epilepsy.ie. 
Understanding 
epilepsy
As preparations begin for national Epilepsy 
Awareness week, which takes place from May 16 to 
22, Mary O’Keeffe takes a look at this condition and 
finds out what pharmacists need to know about 
epilepsy. 
The drug treatment 
of epilepsy is 
very complex and while 
the lucky ones are 
maintained on one drug, 
some will need two or 
three and often there are 
a lot of interactions with 
some of these drugs. 
“
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dr Martin henman , Senior lecturer, School of pharmacy at trinity College, 
Brendan o’Connell, Managing director at Allphar Services, Elaine Condon, 
Allphar Services, tony Fraser, general Manager at hrA pharma uK & Ireland 
and Francois vuillet , International operation director, hrA pharm at the 
recent emergency hormonal contraception education evening, which was 
held at the Westin in dublin. 
hpAI conference 2011Emergency contraception 
education evening Katie tutty, South tipperary 
hospital and pat 
Norris, B.Braun 
at the hpAI 
conference 2011 
at the Crowne 
plaza, Santry, 
dublin this April.
Elaine Conyard 
president of the 
hpAI and Marita 
Kinsella at the 
hpAI conference 
2011 at the 
Crowne plaza, 
Santry, dublin 
this April.
pharmacy liasons course 
pictured at the introduction 
course for pharmacy 
liaisons in the Clinical 
Care programmes, hosted 
by the royal College of 
physicians of Ireland in 
Association with the health 
Service Executive and the 
pharmaceutical Society of 
Ireland was  dr. helen Flint, 
Medication Management 
programme leader, and 
dr. Ambrose Mcloughlin, 
registrar & CEo pSI.
Mr. Tim Delaney, National Programme Lead Medication Safety, 
Shaun Flanagan, Chief Pharmacist, Corporate Pharmaceutical Unit 
HSE, and Dr. Ambrose McLoughlin, Registrar & CEO PSI.
Elaine 
Conyard, 
Sinead 
McCool, 
and Kate 
Mulvenna.
Mark Ledwidge, Leonora O' Brien, and Peter Weedle.
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NAhpt annual conference 2011 
Avril duignan, Fresenus-Kabi, Fiona Fahy, 
pharmacy technician, Bons Secour, galway
Ann o’Brien, pharmacy technician, Mater 
public, Jean Baptiste gicondo, dIt Student 
pharmacy technician
Marie Mclaughlin, pharmacy technician, 
galway university hospital, Eglina 
Corrigan, pharmacy technician, galway 
university hospital
tracy Kivlehan, teva, yvonne, Kavanagh, teva, Ciara 
devlin, gerard labs
Amanuel tesfamariam, dIt Student 
pharmacy technician, Kulbeer Sindh, St 
James’, pharmacy technician
Catherine Field, pharmacy technician, 
Mater public, Carmel Bogue, pharmacy 
technician, Cuh, Niamh McAuliffe, 
pharmacy technician, St vincents
Sheila McCann, 
pharmacy technician 
Altnagelvin hsop, 
derry, Julie Jordan, 
Northern Ireland Centre 
for pharmacy learning 
and development, 
helen Wilson, lecturer 
at South Eastern 
regional College, 
and Caroline hoey, 
Entrant into the poster 
competition
Sarah o’Sullivan, pharmacy technician, St 
James’, Eilish Nolan, pharmacy technician, 
St Michaels hosp, dún laoghaire
Eileen Maher, pharmacy technician, 
Athlone, diane patterson, lecturer in 
pharmacy practice, Athlone, Nicola 
Cantwell, lecturer in regulations and 
dispensing, It Carlow
Jurate godeliauskaite, pharmacy 
technician, Mullingar hospital, Catriona 
Burke, pharmacy technician, tullamore
Elisha dunne, Student pharmacy 
technician, Athlone It, gillian Small, 
Student pharmacy technician, Athlone It
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professor Marek radomski, head of the 
School of pharmacy at trinity College 
dublin held a reception for his Senior 
Sophister year to wish them success in their 
forthcoming final examinations and in their 
future careers. the reception was held in 
the school’s atrium recently and attended 
by several of the school’s academics. 
Antoinette Sweeney AIt and Christina Burke, 
Barrister and law lecturer.
dr. pearse Murphy, head of dept of Nursing & health Science AIt, diane patterson MpSI, 
AIt, president of AIt prof Ciaráin Ó Catháin and conference speakers  debbie graham, Irish 
pharmacy News, Christine Burke, Barrister and law lecturer AIt and Emmet Feerick MpSI 
drugsaver.
Pics: Padraig Devaney.
 representing Kelly's pharmacy Castleisland Co. 
Kerry and Corrs pharmacy Co. louth.
tCd's Class of 2011
AIt's pharmacy 
technician 
conference
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Irish language depression support 
booklet launched
Popular presenters Dáithí Ó Sé and Síle Seoige recently launched an Irish 
language depression support booklet, ‘How to Say lean on Me’. Part of the 
mental health awareness campaign ‘lean on Me’ aimed at encouraging 
friends and family to support those affected by depression, this leaflet 
provides information on how to begin a conversation about depression, as 
Gaeilge. It is estimated that 400,000 people in Ireland experience depression 
at any one time. 
Speaking at the launch of the booklet Síle Seoige commented, “I’m 
delighted to support lean on Me and am particularly pleased to see this 
valuable resource available in Irish. It can be difficult to know how to 
broach the subject of depression with a loved one but this booklet provides 
practical advice on how to talk, listen and above all support.” 
Dáithí Ó Sé explained why he supports lean on Me: “We all know 
someone who has been affected by depression and support and 
understanding from family and friends plays a vital role in their recovery. 
Just being there can make a significant difference to someone with 
depression.”
Kerry based GP Dr Conor Brosnan also welcomed the launch of the 
booklet: “This is a great resource for anyone who is anxious that a loved one 
may be experiencing depression,” he said. “I encourage anyone who has 
concerns about family or friends to begin that conversation and encourage 
them to see their GP.” 
The lean on Me campaign, supported by lundbeck Ireland and Aware, 
was developed to dispel the myths surrounding depression. The campaign 
was initially developed following a survey which looked at the prevalence of 
depression, stigma surrounding the condition and the support experienced 
by those affected by depression. The survey found that almost half of 
respondents (48%) said that they had experienced depression at some time 
in their lives, with over 80% of respondents saying that they knew someone 
affected by depression. 
The survey also found that over half (55%) of those who had experienced 
depression at some point in their life, did not tell their family and friends, 
with 75% saying that they withdrew from family and friends. There were 
a number of reasons for this: 57% didn’t want to burden them with their 
problems, 29% didn’t know how to tell them, 28% saying they were too 
scared, ashamed or overwhelmed, 18% thought they would not understand 
and would turn away from them. 
new face for ear care leader – Cerumol
Ireland’s leading ear wax removal brand, Cerumol, has a new modern face. 
The original formula has been marketed in Ireland for many years and now 
accounts for more than half of all sales in its category according to IMS 
data and sells more than two and half times more units than its nearest 
competitor. The current packaging was however very 
dated and, according to manufacturers Thornton & 
Ross ltd, much in need of a facelift. The new packs will 
appear on shelves from May. 
The new pack design 
harmonises the original 
ear drops with the Olive Oil 
Ear Drops variant that was 
introduced in October 2009. 
That newer variant provides 
a convenient, ready-to-use 
presentation of medical 
grade olive oil suitable for 
those customers who have 
been specifically advised 
“to use olive oil” prior to 
syringing. 
For more information contact Allphar Services (01) 468 8472.
Ricola – now available exclusively from 
Ocean Healthcare
Founded in 1930 by Emil Richterich, Swiss confectioner 
Ricola has been creating its naturally refreshing sweets 
for more than eighty years. Ricola is now the second 
largest sugar confectionary brand in Europe.
Formulated with a unique blend of 13 different Swiss 
herbs, including cowslip, mallow and peppermint 
– the delicious range combines the finest natural 
ingredients with mouth-watering flavours for a 
scrumptious and naturally good treat. Ricola is sugar 
free.
Ricola Swiss Herb Drops gives a refreshing great 
taste that is sure to calm even the most stressful 
of days. They are the ideal sweet treat and mouth 
freshener, whether you’re out and about, at home or 
in the office.
Available in convenient click-shut boxes – making 
them perfect for an on-the-go burst of refreshment – 
Ricola Swiss Herb Drops come in three mouth-watering 
flavours which include tempting choices such as lemon 
Mint, Elderflower plus the distinctive Original Swiss Herb 
Drops.
Ricola is famed for its use of premium ingredients 
and still insists on using only the herbs grown by its 
independent farmers in the Swiss Alps.
The sweets contain no artificial colours or flavours, and 
are suitable for 
vegetarians. They also carry the 
Toothfriendly badge and, with 
only 6 calories per drop, are a 
great guilt-free treat.
Special promotional offers 
are available through Ocean 
Healthcare including a metal 
display unit.
 
For further details and 
POS material contact Ocean 
Healthcare at 01-2968080 or 
info@oceanhealthcare.ie . 
Ricola is also available through 
the wholesalers. 
pictured here are popular presenters dáithí o Sé and Sile Seoige with 
Eithne Boyan, Managing director, lundbeck (Ireland) ltd to launch 
an Irish language depression support booklet, “how to Say lean on 
Me”. part of the mental health awareness campaign “lean on Me” 
aimed at encouraging friends and family to support those affected 
by depression. this leaflet provides information on how to begin a 
conversation about depression, as gaeilge. 
Gentle yet effective, Cerumol is  
Ireland’s number 1 ear wax brand1
Ask your Allphar representative for ordering information, or call (01) 468 8472
With medicinal grade olive oil in a  
patient-ready pack, including dropper 
Reference: 1. IMS data Dec 2010  Cerumol Ear Drops: Each bottle contains Arachis Oil 57.3% & Chlorobutanol 5.0%. Indications: For the loosening and removal of ear wax. Precautions: Do not use for more than three days without 
consulting your doctor. Cerumol contains Arachis oil (peanut oil) and should not be taken by patients known to be allergic to peanut or Soya, the wax plug may cause deafness. Contraindications: Otitis externa, Seborrhoeic dermatitis, 
eczema, perforated ear drum. Side effects: local irritation, redness or rash. PA/610/18/1. Legal Category: P Further information is available from: Thornton & Ross Limited, Linthwaite, Huddersfield HD7 5QH UK Tel: 00 44 1484 842217
Recommend Cerumol
the benefits are loud and clear
“ ”
Wax build-up can seriously  
affect a person’s hearing
“
”
NEW 
distinctive 
pack
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Okuda takes the helm at Roche 
Roche Products (Ireland) 
limited has announced the 
appointment of Osamu Okuda 
as General Manager of the 
Dublin-based pharmaceutical 
company. 
Dr Okuda joins Roche from 
another company within 
the Roche group, Chugai 
Pharmaceutical Co., ltd., which 
is based in Tokyo, Japan. 
Dr Okuda graduated from 
Gifu Pharmaceutical University 
and later received a PhD in 
pharmaceutical science from 
Osaka University in Japan. 
He joined Chugai in 1987 and 
worked in various roles in global 
and local clinical research, 
business development and 
lifecycle management. 
Mark Rodgers will remain in 
Roche as Executive Chairman 
until his retirement at the end 
of June 2011. Roche wishes 
to thank him for his valuable 
contributions to Roche during 
his 35-year career.
 osamu okuda appointed as 
general Manager of roche 
products (Ireland) limited, 
succeeding Mark rodgers who will 
retire from the organisation as 
Executive Chairman at the end of 
June 2011
nEW liftActiv Derm Source with 5% 
Rhamnose
 
Vichy laboratoires has 
identified the active 
ingredient of plant origin 
capable of re-activating the 
Derm Source: Rhamnose 
5%. The Derm Source plays 
the most important role 
in skin’s youthfulness – a 
groundbreaking discovery 
that brings a step change to 
our understanding of skin 
ageing. Benefiting from this 
new discovery, new liftActiv 
Derm Source delivers 
unprecedented anti-wrinkle 
and firmness results.
nEW liftActiv Derm Source, available in pharmacies from 18th April, 
provides reinforced anti-wrinkle and firming effectiveness for a long-
lasting lifting effect. The 5 commonly observed types of wrinkles on the 
face and neck are visibly reduced with up to 20% reduction in 2 months 
(clinical scoring on depth, number and length of wrinkles). Skin feels fully 
transformed: replenished, velvety smooth and luminous.
located in the superficial dermis, one particular group of cells called 
papillary fibroblasts play a previously unsuspected but critical role in 
maintaining skin’s youthful appearance. Vichy has named it the Derm 
Source. Knowledge from this discovery has led to identifying the most 
effective molecule to support and qualitatively regenerate these cells: 
Rhamnose concentrated at 5%. By reactivating the Derm Source, Rhamnose 
5% acts at the very source of skin’s youthfulness revealing its exceptional 
anti-ageing properties.
This discovery represents a new era in the understanding of how skin 
ages. It is the fruit of over 10 years of research by a dedicated team of l’Oreal 
Research scientists and has been enabled by dramatic new advances in bio-
technology.
Knowing which cells are critical to skin regeneration, following 
experimental techniques constructing laboratory skin models, has allowed 
the team to screen large numbers of compounds to find and formulate the 
one that most effectively stimulates the activity of the cells of the Derm 
Source. From the Derm Source, new cells are created as well as new fibres 
and vital exchanges between every layer of the skin. It plays a central role in 
determining the quality of every skin layer, which is why it can be defined as 
the source of skin’s youthfulness. This aspect of the research involved 7 clinical 
studiesand two further placebo-controlled double blind in vivo studies as well as 
laboratory based experiments. It has generated 7 patents.
Vichy has transposed this scientific discovery into a daily anti-wrinkle and 
firming care nEW liftActiv Derm Source. They found an ingredient which 
precisely activates the papillary fibroblasts located in the superficial dermis – 
the very source of skin youth – the ‘Derm Source’.
Rhamnose – Highly 
concentrated at 5%. Using 
techniques used in the 
pharmaceutical industry 
to review thousands of 
molecules, one particular 
ingredient seemed to have 
a major effect on the activity 
of papillary fibroblasts. After 
screening more than 50 anti-
ageing molecules, Rhamnose 
in 5% concentration was 
identified as the most 
powerful ingredient capable 
of specifically targeting and 
reactivating the Derm Source.
limited edition Marc Jacobs tote in aid 
of breast cancer
Brown Thomas has announced that this year it has 
teamed up with celebrated new york Designer 
Marc Jacobs to create a ‘global exclusive’ for the 
7th annual Fashion Targets Breast Cancer Ireland 
Campaign. 
The limited edition quirky packable tote 
features the designer’s signature character, Miss 
Marc, wearing a ‘Fight like a Girl’ tank 
and red boxing gloves. Don’t let Miss 
Marc’s big grin fool you, she is feisty 
and tough – and most importantly, 
she’s a survivor. Her power: all of the 
proceeds from the sale of these special 
designer totes, which will retail for 
€35, will go to Action Breast Cancer 
(a programme of the Irish Cancer 
Society) and Europa Donna Ireland 
(raising awareness of breast cancer 
issues in Ireland). now that’s a cause 
worth fighting for! The tote will be 
launched exclusively at Brown Thomas 
and BT2 stores on Fashion Targets 
Friday, May 6th 2011. 
Melfen 200mg/400mg tablets change 
in presentation
Clonmel Healthcare have announced that Melfen 200mg and 400mg tablets 
are being changed from a pink sugar coated tablet printed with a Clonmel 
logo and code 178 or 179 to a white film-coated tablet that is unprinted.
Please note that the cartons will have nEW FORMUlATIOn printed on 
them also.
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Congratulations to the winner of last month’s crossword: 
Marc Veale of Superpharm Chemist, Unit 8, Main SC, Finglas Village, Dublin 11
For a chance to win €70, please send completed entries by 20 May 2011 to: 
the Editor, Irish Pharmacist, GreenCross Publishing
7 Adelaide Court, Adelaide Rd, Dublin 2 or 
fax to (01) 478 9449.
Please note the winner's cheque will be issued 45 days after publication.
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Across
6 Atrial pouch sounds like oracle (7)
7 Plastic for old records found in V.I. nylon (5)
9 Skin disorder from broken cane. (4)
10 Cricket match and london underground form 
laboratory utensil! (4,4)
11 The sign of the heavenly twins (6)
13 Collapse during autumn? (4)
15 Confused Dane depicts Middle East port (4)
16 Insect sounds like old pop star! (6)
18 One would be spineless without one! (8)
21 Terribly vain Russian (4)
22 His name is Bond, ..... Bond! (5)
23 Acute infection of small intestine from leach or 
ingredients (7)
down
1 There’s no need to qualify how this doctor 
practices! (5)
2 It needs one more for a score! (8)
3 Bloody idiot? (4)
4 How to lose weight with the turn of the tide? (4)
5 Sphere of vision? (7)
8 Have ambitions standing in O’ Connell Str et? (6)
12 Drink in denim bib eagerly (6)
13 Coil fell awkwardly to form a small sac (8)
14 Dale ran amok for a type of gland (7)
17 Godmother, liquid or tale (5)
19 Mete out a heavy shower (4)
20 Continuous pain during stomach examination! (4)
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ip Crossword No.186
MAy
Saturday, May 7 and and 
Sunday, May 8 
Ipu National pharmacy 
Conference 
The Irish Pharmacy Union 
is hosting the inaugural IPU 
national Pharmacy Conference 
on the 7th and 8th May 2011. 
The Conference will take 
place in the lyrath Estate 
Hotel, Kilkenny. The two-day 
Conference is a new initiative 
by the Union and the only 
one of its kind in Ireland. The 
programme has a variety of 
things to satisfy your curiosity, 
whether it’s Continuing 
Education sessions, Business 
sessions, a Panel Discussion 
on current pharmacy issues 
or the IPU AGM. A Gala Dinner 
will also be held on the night 
of 7 May.
Sunday, May 1 to Tuesday, 
May 31 
Bealtaine
Bealtaine, the arts festival 
for older people in the 
community will take place 
this May. A number of events 
will take place across the 
country as part of this unique 
Irish festival. For further 
information log on to www.
olderinireland.ie, e-mail info@
ageandopportunity.ie or call 
01-8057709. 
Monday, May 2 to Monday, 
May 16
Sunsmart campaign 
The Irish Cancer Society will 
run their annual Sunsmart 
and skin cancer awareness 
campaign this May. For further 
information log on to www.
cancer.ie. 
Saturday and Sunday, May 
7th and 8th 
Ipu National pharmacy 
Conference 
The Irish Pharmacy Union is 
hosting the inaugural IPU 
national Pharmacy Conference 
on the 7th and 8th May 2011. 
The Conference will take 
place in the lyrath Estate 
Hotel, Kilkenny. The two-day 
Conference is a new initiative 
by the Union and the only 
one of its kind in Ireland. The 
programme has a variety of 
things to satisfy your curiosity, 
whether it’s Continuing 
Education sessions, Business 
sessions, a Panel Discussion 
on current pharmacy issues 
or the IPU AGM. A Gala Dinner 
will also be held on the night 
of 7 May.
May 16 to 22
National Epilepsy Week 
Brainwave, the Irish Epilepsy 
Association will host a number 
of outreach clinics, seminars 
and information evenings 
this month to mark national 
epilepsy week. For a full list 
of events contact Brainwave 
on 01-4557500 e-mail info@
epilepsy.ie or log on to www.
epilepsy.ie
Wednesday, May 25
the origin of drugs lecture 
The Royal College of Surgeons 
will host a public lecture 
this month on the origin of 
drugs. The lecture, which will 
be presented by Dr. Celine 
Marmion, Department of 
Pharmaceutical & Medicinal 
Chemistry, RCSI will take place 
on Wednesday, May 25 at 7pm 
at the RCSI.
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SuMMEr 2011
lady pharmacists golf 
Society, leinster 
The lady Pharmacists Golf 
Society will hold a number of 
outings this summer. 
The first of these will take 
place on Saturday, 28th of 
May at Glasson Golf Club. On 
Saturday, 23rd of July, the 
society will meet at Druid’s 
Glen Golf Club. Another 
outing will take place at 
Mount Wolseley Golf Club on 
Saturday, 20th of August. 
For further information 
contact Doreen O’Donoghue, 
Competition Secretary on 086 
623 6896 or Ann O’Connor Hon. 
Sec. 087 232 6483.
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opinion OUTsIdE EdGE
FINTAN MOORE
Still on the cutting edge
under the Spotlight
The other professions in the IMF spotlight are the 
legal and medical. Given that in any contest against 
the government the legal profession has written the 
rules, owns the pitch, selects both teams and supplies 
the referee we can guess who the winner will be 
on that one. The fate of the doctors could be more 
interesting. I have to admire the ability of doctors to 
present any cuts in HSE payments as a direct attack 
on patient services. The FEMPI cut earlier this year of 
€48 million off GP fees was even suggested by the 
Irish Times editor as being incompatible with the 
supposed desire for increased primary care services. 
Granted, €48 million is a big number, but there are 
over 2,600 GP GMS contracts in the country, so it 
represents an annual cut of less than ten per cent, or 
€20,000 per contract. This is less than each pharmacy 
is set to lose under FEMPI 2011, let alone what we 
have lost since 2009.
I have visions of a machete-hacked pharmacist 
staggering into a GP’s surgery for treatment. The 
conversation goes as follows…
Pharmacist – ‘Help, my arm is hanging off. I’m 
bleeding to death.’
GP – ‘Hmmm, yes, I daresay that must sting a bit. I 
know just how you feel – why just this morning I was 
shaving and I nicked my chin. Took ages to stop the 
blood.’
Pharmacist – ‘What can you do for me?’
GP – ‘Oh these hatchet wounds just take their 
course. We all have to just get on with things . There’s 
a colleague of mine was opening an envelope 
yesterday and the edge of the paper cut his finger 
quite badly. He’s fine again now, but it goes to show.’
Pharmacist – ‘I think I better go before I faint.’
GP – ‘Faint eh? yes, the sight of blood can do that, 
even for a professional like myself. I was pruning a 
rose bush at the weekend and pricked myself on a 
thorn. Right into the thumb. Excruciating. Oh, you’re 
leaving? Have a nice day. you can pay the receptionist 
on the way out.’
StealS on wheelS
last June my pharmacy (in Clondalkin) was raided by 
a lone scumbag wearing a motorcycle helmet and a 
red and white jacket. The same guy raided another 
pharmacy in Clondalkin in March this year in exactly 
the same way. He has been arrested and charged with 
both robberies. I may be wrong, but it seems unlikely 
to me that he didn’t commit any other robberies 
between June and March. If any of this sounds 
familiar then it might be worth a call to Clondalkin 
Garda station.
On the subject of raids, I recently got an access 
control for the door of my pharmacy. I had never been 
too keen on these as I didn’t like the idea of a ‘barrier’ 
to entry for people. However, having had it for a few 
weeks now I find that it does give a lot of peace of 
mind, especially on dark evenings, or those occasions 
when a customer tells you that ‘there’s a couple of 
dodgy-lookin fellas in a car around the side of the 
shops.’ no system is fool-proof, but if in doubt I would 
recommend getting it installed. 
S
o FEMPI 2011 has arrived and the HSE has 
sliced another annual €36 million out 
of the pharmacy sector. This is of course 
on top of the €133 million per annum 
gone since 2009. And this is not yet the 
end of the line; we are still faced with the 
unknown losses to be caused by reference pricing. 
There is also the bizarre fact that the country’s bailout 
deal from the IMF seems to hinge on Olli Rehn being 
happy that pharmacists no longer have a fifty per 
cent mark-up on dispensed medication in order 
to make the country competitive again. It is pretty 
obvious that Olli didn’t come up with this gem on 
his own, so we are clearly still being targeted by low 
foes in high places. It would be interesting to know 
just what these people think is an acceptable level of 
profit for a pharmacy so that we can see whether it’s 
worth our while trying to stay in business or whether 
we should just begin an orderly wind-down of our 
affairs now.
Given that what mark-up we charge on our 
private business is of no relevance to government 
expenditure, then why are lots of other retailers not 
in the firing line? There are some very obvious areas 
of household expenditure that could be reduced to 
improve competitiveness. What’s the standard ball 
park mark-up charged on home-heating oil, petrol, 
newspapers, bread, meat, milk, wine, nappies etc.? It 
makes as much sense to go after all of these as it does 
to target us, but I won’t be holding my breath.
